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Delivery of therapeutical oligonucleotides to the central nervous system is challenging due 
to their inability to cross the blood-brain barrier. Current approaches to overcome this 
problem disturb the blood-brain barrier, administer too low dose for therapeutic purposes 
or have serious side effects. Therefore, nanocarriers, that are able to penetrate the blood-
brain barrier, can be used to deliver them. Hence, the aim of this study was to investigate 
the potential of ~2 nm galactose-coated gold nanoparticles (NP-Gal) as a delivery system 
of oligonucleotides into the brain. 
DNA oligonucleotides were attached to the NP-Gal via place exchange reaction. Several 
nanoparticle formulations were created, such as 20nt single-stranded versus double 
stranded versions of DNA-coated gold nanoparticles (NP-DNA-20ss, NP-DNA-20ds) and 
40nt long double stranded versions of DNA-coated gold nanoparticles (NP-DNA-40ds). 
These were analysed by (1) electrophoresis mobility shift assay (for detection of 
nanoparticles with different numbers of DNA molecules), and (2) fast protein liquid 
chromatography (for isolation of NP-DNA-40ds) forming two fractionated formulations - 
low-density 40nt DNA nanoparticle formulation (NP-DNA-40LO) and high-density 40nt 
DNA nanoparticle formulation (NP-DNA-40HI). The rate and route of transport across 
brain endothelial cells (hCMEC/D3) was assessed by transmission electron microscopy. A 
3D co-culture model of the blood brain barrier was used to detect nanoparticle uptake into 
astrocytes once they passed through brain endothelial cells. Next, we performed in vivo 
examination of tissue distribution of the nanoparticles following intracarotid and 
intravascular infusion (using ICP mass spectroscopy along with light and electron 
microscopy). Lastly, qPCR was used to quantify transport rate and efficiency of DNA 
cargo across brain endothelial cells. 
DNA oligonucleotides attached to NP-Gal by place exchange reaction produced six 
different nanoparticle formulations. The cell uptake efficiency of NP-DNA-20ss, NP-DNA-
20ds and NP-DNA-40ds was compared; the more negatively-charged DNA bound 
nanoparticles had increased cellular uptake in human brain endothelial cells compared with 
the NP-Gal. This investigation pointed out the possibility that attaching more DNA onto 
each nanoparticle may increase the uptake efficiency of NP-Gal by brain endothelium. The 
transport rate of DNA nanoparticles free of unreacted DNA and nanoparticles - NP-DNA-
40LO and NP-DNA-40HI was compared to the NP-Gal using a 3D co-culture model of 
blood-brain barrier. Both the NP-DNA-40LO and NP-DNA-40HI were more effective in 
crossing the brain endothelial cells and entering astrocytes compared to NP-Gal. Moreover, 
we found our nanoparticles to be not cytotoxic for hCMEC/D3 at the dose used in our 
studies (8µg/mL). Next, we investigated tissue localization of NP-Gal, NP-DNA-40LO and 
NP-DNA-40HI 10 minutes after intravascular infusion in rats. All three nanoparticles 
formulations localised in the brain endothelial cells and glial cells of the cortex. While NP-
Gal were mainly found in the kidney, DNA-coated nanoparticles were found in the 
cytoplasm of liver hepatocytes and macrophages of the red pulp in the spleen. Lastly, we 
found that DNA cargo can be successfully delivered across brain endothelial cells. NP-
DNA-40LO and NP-DNA-40HI carried over half of the DNA applied (apical side) across the 
brain endothelium. In conclusion, our study demonstrated the possibility to deliver 40nt 
DNA oligonucleotide across the blood-brain barrier using a 2nm gold nanocarrier. There 
was improvement in the bioavailability of oligonucleotides across the brain endothelial 
cells carried by NP-DNA-40LO and NP-DNA-40HI compared to naked DNA in vitro. In 
vivo, we found similar brain penetration of NP-Gal, NP-DNA-40LO and NP-DNA-40HI so 
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1 GENERAL INTRODUCTION 
Drug delivery to the brain is drawing major attention, and researchers are working on how 
to solve the issues of treating central nervous system (CNS) diseases. Currently, CNS 
diseases account for a large proportion of disease burden and societal costs, with a 
proportionally lower research budget than other disease areas (Feigin et al, 2019). Several 
pharmaceutical companies are stopping or significantly reducing major efforts in the area 
of CNS diseases due to difficulties in drug delivery. Not a single pharmaceutical company 
worldwide has a drug-discovery programme targeting the blood brain barrier therefore, the 
area needs attention and that collaboration and new knowledge is needed to understand and 
handle these issues in the future.  
The real obstacle of delivering drugs into the CNS is the blood-brain barrier, which 
consists of endothelial cells, astrocytes and pericytes with tight junctions (Pardridge W. M, 
2005). It forms a highly selective semipermeable membrane barrier that protects the brain 
from brain-disrupting compounds found in the blood. It acts as a kind of ‘firewall’, which 
allows the passage of oxygen and essential nutrients into the brain, but at the same time 
blocks the entrance of most of the harmful or toxic molecules into the brain. Therefore, it 
prevents the entry of about 98% of drugs from crossing the BBB pathway (Pardridge W. 
M, 2005). Thus, large molecules, monoclonal antibodies, gene therapies, recombinant 
proteins, antisense and RNA interference compounds cannot cross through the BBB. 
Researchers have come up with several potential agents to treat CNS diseases but end up 
running into a major roadblock when trying to deliver them to the nervous system 
(Pardridge W. M, 2005). 
Limited strategies designed to deliver therapeutics into the brain exist, either invasive or 
non-invasive. The invasive route involves administering drug directly into the brain 
through surgical intracerebral injection, which provides a sufficient dosage of the drug 
without causing systemic toxicity (Agrawal et al, 2018). However, intracerebral injection is 
painful and complicated procedure and relies mainly on cerebral diffusion, hence being 
dependant on the concentration which can decrease from the site of administration. Non-
invasive strategies include systemic drug delivery, based on the anatomical structure of 
brain capillaries, cells, and extracellular environment and the nasal route to transfer fluids 
across the brain using the olfactory bulb (Agrawal et al, 2018). The limitations of nasal 
delivery include inadequate drug infusion through the nasal mucosa, and that drug 
clearance might occur without reaching the site of interest. For the systemic drug delivery 
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to work effectively, the drugs need to enter the brain parenchyma and the cerebrospinal 
fluid and further diffuse through the brain extracellular matrix to the targeted site (Agrawal 
et al, 2018). Although there are multiple crossing pathways (detailed in chapter 1.1.3), yet 
approximately 98% of small molecules and most large molecules are unable to reach the 
brain through the BBB (Pardridge W. M, 2005). 
Gene editing or gene silencing through nucleic acids currently is one of the promising 
approaches to treat neurodegenerative diseases. However, securing consistent delivery into 
the CNS presents several challenges. One of the potential ways to cross BBB without 
affecting its properties is to use nanoparticles as nanocarriers to deliver therapeutics into 
the brain. Here in this thesis we focused on gold nanoparticles as nanocarriers to deliver 
therapeutic oligonucleotides into the brain.   
 
 
1.1 Blood-Brain Barrier 
The CNS has developed a series of barriers to protect itself from invading pathogens, 
neurotoxic molecules, and circulating blood cells. The CNS structure, with diverse degrees 
of permeability, includes the blood-cerebrospinal fluid (CSF) barrier, the blood-brain 
barrier (BBB), the blood-retinal barrier and the blood–spinal cord barrier (Abbott et al., 
2010). Of the three main CNS barrier layers, the BBB at the brain endothelium is the most 
crucial interface for molecular fluxes between blood and cells as a result of the very 
extensive microvascular bed, and proximity of the finest branches to individual neurons, 
typically 8– 25μm (Abbott et al., 2010). 
The first evidence for a BBB arose in 1885 when Paul Ehrlich described the existence of a 
physical interface between the CNS and the peripheral circulation (Serlin et al., 2016). 
Ehrlich injected aniline dyes into a rat’s bloodstream to stain tissues. Surprisingly, the dye 
injected into the blood circulatory system stained peripheral organs but not the brain and 
the spinal cord. 
Thirty years later, Ehrlich’s student, Edwin Goldmann, noticed the opposite phenomenon 
by injecting trypan blue into the cerebrospinal fluid (CSF), which stained cells within the 
CNS, but not in the periphery (Serlin et al., 2016). The two experiments showed that a tight 
seal existed between the blood and the brain. However, the nature of that seal did not 
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become apparent until the late 1960s, when electron micrographs of brain capillaries 
revealed that they differ from capillaries in the rest of the body. The endothelial cells that 
make up the walls of brain capillaries form tight junctions, restricting the passage of ions 
and many metabolites and biomolecules between the cells of the endothelium. 
The BBB structure is formed by a complex system of endothelial cells, pericytes, 
astrocytes, and basal lamina (Masserini, 2013), preventing the passage of most circulating 
cells and blood-borne molecules (de Boer & Breimer, 1998; Petty & Lo, 2002). This is 
achieved by the presence of tight junctions between brain endothelial cells interconnected 
side by side to form a seal, which restricts the paracellular movement of molecules. Next, 
specialized transporters and the efflux transporters control substances that enter the brain. 
Lastly, enzymatic components protect the brain from toxins or neurotransmitters (Hersh et 
al., 2016)  
 








1.1.1 Building blocks of the Blood-Brain Barrier 
 Brain endothelial cells – the BBB is made up of endothelial cells that form the 
walls of the capillaries. These cells are required for proper barrier formation and 
interaction with adjacent cells. The brain endothelial cells have continuous tight 
junctions. Tight junctions between the brain endothelial cells prevent paracellular 
movement of molecules and restrict passive diffusion of molecules into the brain. 
Brain endothelial cells also help to shuttle essential nutrients and metabolites across 
the BBB, via their ATP-binding cassette (ABC) transporters (Abbott et al., 2010). 
These transporters contribute to the BBB properties by efflux of small lipophilic 
molecules that can diffuse into the brain endothelial cells and back to the 
bloodstream. Although the endothelial cells form the primary barrier of the BBB, 
they also interact with surrounding cells (Abbott et al., 2010), including astrocytes 
and pericytes, which contribute to the maintenance of the barrier function (figure 
1.1).  
 Basal lamina is made up of type IV collagen, fibronectin, and laminin that cover 
the whole capillary endothelial cell layer, keeping the BBB structure integral. The 
primary function of the basal lamina is to restrict the movement of solutes 
(Cardoso, Brites, & Brito, 2010). 
 Pericytes are embedded in basal lamina forming a cellular layer around the 
endothelial cells. They play an essential role in the formation and maintenance of 
the BBB. Their contractile properties also help to regulate capillary blood flow and 
phagocytosis, clearing out cellular debris as well as inhibiting any CNS immune 
cells from damaging the proper formation of BBB (Liu et al, 2012). 
 Astrocytic End-Feet are processes extended by astrocytes – the star-shaped glial 
cells found in the brain and spinal cord. Astrocytes have various roles, but mostly 
they support neurons (Cardoso, Brites, & Brito, 2010). Their other functions 
include biochemical support of the brain endothelial cells, providing essential 
nutrients to the nervous tissues, maintaining a balance of extracellular ions, and a 
role in scarring and repair processes of the brain following traumatic injuries 






1.1.2 Molecular Composition of BBB 
The vital components of the BBB are tight junctions between brain endothelial cells, which 
restrict the paracellular diffusional movement of molecules passing between the 
endothelial cells, from blood to brain. The effectiveness and integrity of these tight 
junctions are controlled by transmembrane and cytoplasmic accessory proteins, which help 
to form a tight seal by linking to intracellular actin and the cytoskeleton (Cardoso, Brites, 
& Brito, 2010). The transmembrane proteins include occludin, claudin, and junction 
adhesion molecules (JAM). Occludin helps with only the formation of tight junctions, 
whereas JAM and claudin (claudin-1 and claudin-5) help with both formation of tight 
junctions and contribute to creating the BBB high electrical resistance (Cardoso, Brites, & 
Brito, 2010). Besides this, there are also cytoplasmic accessory proteins, which include 
Zona occludens (ZO-1, ZO-2 and ZO-3) and cingulin, which are necessary for the 
structural support (Kaur, Foulds, & Ling, 2008). Cytoplasmic proteins play a vital role in 
the structural support of tight junctions and creating low permeability of the BBB. The 
absence of cytoplasmic proteins can cause disruption of the tight junctions and thereby 
permit the entry of infected monocytes into the CNS (Wolburg & Lippoldt, 2002). 
The BBB structure also includes adherens junctions, which are located on the endothelial 
cells, and which contribute to the structural integrity of the tight junction. The adherens 
junction complex is composed of cadherin proteins. Cadherins are linked to the cytoplasm 
through the association of alpha, beta, and gamma catenins, allowing cell-cell adhesion and 
ensuring tissue structural support (Wolburg & Lippoldt, 2002). 
Additionally, the presence of tight junctions and their respective trans-membrane proteins 
generate a high electrical resistance across the endothelium. This resistance restricts 
movement of electrolytes across the endothelial cells and reduces ion movements via the 




1.1.3 Routes across blood–brain barrier 
Brain endothelial cells possess many different transport systems in order to supply the 
brain with nutrients. Passage of molecules across the brain endothelial cells can occur via 
the paracellular pathway (between adjacent cells) or through a transcellular pathway 
(through the cells) (Hersh et al., 2016). Paracellular and transcellular pathways play a vital 
role in BBB permeability. In the paracellular pathway, the ions and solutes diffuse between 
two adjacent cells according to their concentration gradient (Petty and Lo, 2002). Whereas, 
the transcellular pathway involves different mechanisms of both passive diffusion of 
lipophilic compounds and receptor mediated shuttling and transcytosis of molecules.  
The passage of all the compounds that cross the brain endothelium via paracellular and 
transcellular pathways can be categorised as passive diffusion, carrier-mediated transport, 
or endocytosis/transcytosis (Gromnicova et al. 2016). 
 
1.1.3.1 Passive diffusion 
Small lipid soluble and non-polar molecules with size less than 500 Da can enter the brain 
through passive diffusion (Pardridge, 2005).  The exchange of the blood gases, oxygen and 
carbon dioxide is diffusive, and these gases move down their concentration gradients. 
Oxygen supply to the brain and carbon dioxide removal is blood-flow dependent, as long 
as cerebral blood flow remains within physiological limits (Pardridge, 2005). 
Usually, higher lipid solubility and several other physico-chemical factors favour the 
process of BBB penetration, but some factors may restrict the passive diffusion of the 
compounds into the CNS. These include; compounds with molecular weight higher than 
500 Da, compounds that have high polar surface area and compounds that have a tendency 
to form 6 or more hydrogen bonds, as having more hydrogen bonds moves the molecule 
from the aqueous phase into the lipid phase of the cell membrane, which can reduce the 
diffusion by increasing the free energy requirement (Pardridge, 2005). However, these 
molecular and physico-chemical factors are not always an absolute indication for CNS 
penetration and there are many examples of effective CNS active drugs in clinical use 
which do not comply with these BBB penetration rules (Bodor, 2010). One example is that 
bases that carry positive charge have an advantage over acids when penetrating the BBB. 
Their cationic nature allows them to interact with the negatively-charged glycocalyx and 
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phospholipids of the plasma membrane of endothelial cell that facilitate their entry 
(Johansson, 2001). 
 
1.1.3.2 Carrier-mediated (solute) transport  
Most hydrophilic or polar molecules, such as peptides and proteins, cannot diffuse through 
cell membranes. Thus, brain endothelial cells express many carrier-mediated transporters 
in the cell membrane (Zhang et al., 2002). The carrier-mediated transporters work by either 
facilitating diffusion or use sodium or proton gradients (Abbott et al. 2010). The 
transported molecules include a wide range of molecules such as glucose, amino acids, 
nucleosides and nucleotides, small peptides, organic cations, and anions (Abbott et al. 
2010). 
Brain endothelial cells express these transport proteins on the luminal and abluminal 
endothelial cell membranes (Cardoso, Brites, & Brito, 2010). The transport of these 
molecules is influx and (going in from blood to the brain) and also efflux (going back into 
the blood from the brain endothelium) or from brain endothelium via specific efflux 
transporters of the ATP-binding cassette (ABC) transporters (Cardoso, Brites, & Brito, 
2010) (figure 1.2). The ones of the greatest significance for efflux transport are P-
glycoprotein (Pgp-1) (i.e. ABCB1), the Multidrug Resistance-associated Proteins (MRPs) 
(i.e. ABCC1), and Breast Cancer Resistance Protein (BRCP) (i.e. ABCG2). These efflux 
transporters are located on the luminal side of the brain endothelial cells. They remove 
lipophilic molecules, including many potentially harmful molecules and drugs from the 
brain endothelium back into the blood (Begley, 2004). These transporters are also 
responsible for excluding useful drugs from entering the brain and present a major 




Figure 1.2 Endothelial cells express a variety of transporters and receptors, which regulate brain 
concentrations of nutrients, hormones, metabolites and xenobiotics. For simplicity, the diagram 
only presents a few of the main transporters and receptors, the glucose transporter-1, the insulin 
receptor, the ABC transporters, the multidrug resistance-associated protein and p-glycoprotein 
(figure taken from Cardoso, Brites, & Brito, 2010). 
 
 
1.1.3.3 Endocytosis and transcytosis  
Large proteins/peptides and macromolecules are transported across the BBB via 
transcytosis. Transcytosis is a transport process that transports large molecular weight 
solutes by two mechanisms; endocytosis (macromolecules are taken up into vesicles) 
and/or exocytosis (vesicles containing macromolecules are released from the cell). 
Transcytosis of macromolecules across the BBB provides the main route by which large 
molecular weight solutes can enter the CNS intact (Abbott et al. 2010). Although most 
large blood-borne molecules are physically prevented from entering the brain by the 
presence of the blood–brain barrier and tight junctions, specific and some non-specific 
transcytosis mechanisms exist to transport a variety of large molecules and complexes 
across the BBB (Abbott et al. 2010).  
The overall mechanism of endocytosis involves molecules being pinched off or coated in a 
vesicle. The vesicular mechanism of transport involves either receptor-mediated 
transcytosis (RMT) or adsorptive-mediated transcytosis (AMT) (Abbott et al. 2010). 
Receptor-mediated transcytosis (RMT) involves a specific receptor, such as transferrin 
receptor or insulin receptor, on the cell surface, which triggers an endocytosis event. The 
receptors and their bound ligand form a cluster and a caveolus is formed, which pinches off 
into a membrane-enclosed vesicle. Then, both the receptor and ligand are internalised into 
the endothelial cell and transported across the cytoplasm to be either exocytosed at the 
opposite side of the cell or moved into a lysosomes to be digested, for the cell to use the 
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nutrients within the vesicle.  In contrast, adsorptive endocytosis involves binding of 
charged macromolecules, which renders macromolecule cationic and causes interaction 
with cell surface binding sites and causes endocytosis (Sauer et al., 2005). The details of 
these transport systems are outlined in Table 1.1. 
 
Table 1.1 Examples of few of the macromolecule systems on the BBB which deliver 
molecules from blood to brain (Sauer et al. 2005). 
Transport system  Receptor (if known)  Ligand  Type  
Transferrin  Transferrin receptor (TfR)  Transferrin-Fe RMT 
Insulin Insulin receptor (IR) Insulin  RMT 
Lactoferrin  Lactoferrin receptor (LfR)  Lactoferrin  RMT 
Tumour necrosis 
factor 
Tumour necrosis factor 
receptor (TNFR) 
TNFα RMT 
Apolipoprotein E  Apolipoprotein E receptor 
2 (ApoER2)  
Lipoproteins  RMT 
LDL-receptor-
related protein 1 and 
2  
LDL-receptor-related 
protein 1 and 2  (LRP1, 
LRP2)  
Lipoproteins, Amyloid-





Cationised proteins + Cationised albumin AMT 
Cell penetrating 
peptides 
+ SynB5/pAnt-(43–58) AMT 
 
Macromolecule transport can be exploited or targeted to overcome the BBB. Examples of 
the most commonly targeted are transferrin receptor or LRP-1 (LDL-receptor-related 
protein 1) receptor. This is because the expression of the transferrin and LRP-1 receptor is 
high in brain endothelium in vivo. (Helms et al. 2016). 
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1.1.4  Enzymatic blood-brain barrier  
In addition to tight Junctions and efflux pathways, brain endothelial cells also express 
various enzymes that can metabolize lipophilic toxic substances or neurotransmitters and 
thus protect the brain. These enzymes are metabolically highly active and are localised in 
large numbers within the cytoplasm of the endothelium, such as peptidase and 
cholinesterase (Pardridge, 2005). These enzymes limit the entry of various endogenous and 
exogenous substances (Pardridge, 2005). Some enzymes functionalize lipophilic 
substrates, such as cytochromes P-450, other enzymes covert metabolites to polar 
molecules, by conjugating them with a small molecule, so that they can be excreted (Minn 
et al. 1991).  
 
 
1.1.5 Models to study the Blood-Brain barrier models for in 
vitro research 
BBB models are used to test drug transport and the simplest way to model a BBB is to use 
brain endothelial cells, as these are the first line of cells that will be in contact with the 
blood and with the tested substances. Using an in vitro cell line of brain endothelium also 
makes it easy to mimic the characteristics of BBB, such as the relative expression of 
molecules that provide the phenotype of brain endothelial cells’ tightness and lack of 
permeability and high electrical resistance (reviewed in Gromnicova, 2016). Also, in vitro 
BBB models reduce animal testing and are overall less expensive than in vivo experiments. 
Since the 1970’s, researchers in both academia and industry have attempted to isolate 
cerebral micro-vessel endothelial cells (CECs) in order to model a human BBB in vitro that 
closely mimics the in vivo phenotype, which is reproducible and easy to grow. Although 
primary human CECs would be an ideal model of choice, the rarity of available fresh 
human cerebral tissue makes the studies impractical.  
On the other hand, brain microvascular endothelial cell line hCMEC/D3 was developed to 
model human BBB. It can be easily grown and is amenable to cellular and molecular 
studies on pathological and drug transport mechanisms with relevance to the central 
nervous system (CNS) (Weksler, Romero, & Couraud, 2013). The immortalised 
hCMEC/D3 cell line retains some important characteristics of primary brain endothelial 
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cells, and expresses cell surface adhesion molecules, tight junction proteins, chemokine 
receptors, ABC transporter proteins, and brain microvascular endothelial markers 
throughout the course of 35 cell-split passages (Sreekanth, 2012). However, hCMEC/D3 
lacks high electrical resistance that primary brain endothelial cells possess.  Despite its 
downside, many researchers have used the cell line since its introduction in 2005 and to 
date; over 500 research articles have been published using hCMEC/D3 cells.  
 
1.1.5.1 3D co culture model of blood-brain barrier 
Cells behave differently in an in vivo environment compared to the monolayer they are 
cultured in (2D environment). Cells in an in vivo environment are in 3D matrix along with 
other cell types of the BBB and therefore, receive physical support, nutrients, and 
biochemical signals from all directions.  
It is possible to mimic 3D in vivo environment for which 3D co-cultures have been 
developed. Using a 3D co-culture model of the BBB can provides a quick solution 
compared to animal experiments in understanding fundamental biology and the 
development of therapeutic products. 3D co-culture model of the BBB can be designed 
using collagen gel cultures seeded with glial cells, astrocytes or pericytes or both. Then, a 
monolayer of hCMEC/D3 cells is seeded on top of the collagen gel (Sreekanth et al, 2012). 
To prepare a 3D co-culture model, hCMEC/D3 can be co-cultured with astrocytes. 
Astrocytes from various sources, including mouse, rat, porcine, bovine, and human, can be 
used. In our project, primary human astrocytes were used as they may potentially increase 
the translational findings to humans in vivo. Primary human astrocytes are obtained from 
brain tissue of a foetus or an adult - in the present study we used human foetal astrocytes 
due to the limited availability of human tissue from the adult brain.  
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1.2 Overcoming the Blood-Brain barrier  
A number of approaches have been developed to improve therapeutic drug delivery across 
the BBB into the CNS. Strategies range from bypassing the BBB to deliver drugs directly 
into the brain, modifying the drug agent and its carrier for effective delivery, or even 
disrupting the BBB itself (illustrated in figure 1.3). All current strategies have their own 
specific features, advantages and limitations that are summarized in the Table 1.2 (Hersh et 
al, 2016). 
 
Table 1.2 Different approaches for drug delivery across BBB into brain featuring their 
advantages and limitations (table taken from Hersh et al, 2016). 
Method Route Advantages Limitations 
Osmotic Disruption of 
BBB 
Paracellular Transient Invasive 
Transient cerebral oedema 
Non-specific 
Chemical Disruption of 
BBB 




Transcellular Targeted Low efficiency 
Cell-mediated delivery Transcellular Targeted Toxicity to cell carrier 
Low therapeutic 
 loading 






Bypass BBB Elevated 





Rapid CSF turnover 
Intranasal Delivery Bypass BBB Non-invasive 
Simple 
administration 
Irritation of nasal 
 mucosa 
Low efficiency 
Interstitial Wafers and 
Microchips 
Bypass BBB Sustained and/or 
 controlled release 
Invasive 
Limited distribution 
 through extracellular space 
Convection Enhanced 
Delivery 
Bypass BBB Enhanced 
distribution 
 via bulk flow 
Invasive 
Back flow of infusate 






Figure 1.3 An illustration of different strategies for delivering therapeutic drugs across the BBB. 
Therapeutic drugs are transported from the blood vessel lumen across the BBB via various 
strategies: osmotic or chemical disruption of tight junctions; receptor-mediated transcytosis; 
nanoparticle-based carriers (including targeted nanoparticles); cell-mediated delivery, and 
Focussed ultrasound-mediated oscillation of microbubbles causing disruption of tight junctions 
and enhanced transcytosis. Interstitial wafers and microchips, in addition to convection-enhanced 
delivery CED, bypass the BBB and deliver therapeutic agents directly to the brain parenchyma 
(figure taken from Hersh et al, 2016). 
 
Although there are multiple drug delivery approaches, approximately 98% of small 
molecules and most large molecules (Pardridge W. M, 2005) are unable to reach the brain 
through the BBB due to various limitations - inadequate drug infusion, being painfully 
invasive or disrupting the BBB.  
 
 
1.2.1 Overcoming the Blood-Brain barrier with nanocarriers 
As discussed before, the BBB prevents many types of molecule from entering the brain. 
Therefore, potential drugs and therapeutic molecules that are designed to target the brain 
must be delivered in a way that overcomes the impermeable BBB. One of the approaches 
to overcome this problem is to use nanocarriers. 
Currently, advances in the field of nanomedicine have generated several platforms that can 
improve the unmet problem of drug transport across the BBB, namely nanoparticles (NPs) 
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(Khan et al. 2014). NPs are colloidal carriers that can have a natural or synthetic origin and 
vary in sizes between 1 and 100 nm (Masserini, 2013). NPs provide a promising approach 
for drug delivery into the brain due to their different functional groups. The possibility of 
drug reaching the brain after coupling with NP will primarily depend on the 
physiochemical features of the NPs that will be carrying the drug rather than on the 
chemical structure of the drug, as in most cases the drug is inactive with the NPs 
(Masserini, 2013). NPs also have high chemical and biological stability. Moreover, they 
can incorporate both hydrophilic and hydrophobic therapeutics and be administered into 
the brain by a variety of routes (including oral, inhalation, and parenteral) (Masserini, 
2013). Moreover, NPs can bind its therapeutic ligands (i.e. cargos) either covalently or 
non-covalently. They can carry proteins, antibodies, aptamers, or nucleic acids to target 
specific tissues. Having a large surface area to volume ratio gives them the ability to bind 
to multiple copies of ligands and dramatically increase their binding affinity (Masserini, 
2013).  
 
There are two types of NPs - synthetic NPs, and natural NPs.  
1. Synthetic NPs can be made from organic or inorganic material;  
 Organic materials NPs - made of polymeric materials such as Poly (e-
caprolactone) (PCL), poly(ethylenimine) (PEI), poly(amidoamine) 
dendrimers (PAMAM), poly(alkylcyanoscrylates), poly(lactic-co-glycolic 
acid) (PLGA) and polyesters (poly(lactic acid) (PLA)).  
 Inorganic materials NPs- made from gold, silver, silicon dioxide (silica). 
These NP carriers can transport therapeutic drugs mainly by adsorbing, entrapping, or 
binding covalently to the therapeutics (Khan et al. 2014). The inorganic NPs offer a great 
advantage over the organic and natural polymeric NPs in terms of simplicity of preparation 
and functionalization. Due to their distinctive physical properties, inorganic NPs are easier 
to track by microscopy (such as transmission electron microscopy (TEM), magnetic 
resonance imaging (MRI)), or analytical techniques (such as ICP-MS). Disadvantages of 
inorganic NPs are that they cannot be degraded naturally, and some might present 
undesired toxicity (such as silver nanoparticles).  
2. Natural NPs – are made from natural polymers such as amino acids (poly(lysine), 
polysaccharides (chitosan and alginate), poly(aspartic acid), or proteins (albumin 
and gelatin) (Khan et al. 2014). The NPs made up of natural materials have 
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advantages of providing biological signals to interact with specific 
receptors/transporters that are expressed on endothelial cells. However, their 
downsides are limited ability to control their modification, inadequate tracking 
capacity on imaging platforms, and batch to batch variability (Khan et al. 2014). 
The types of nanoparticles that are popular for biomedical research are reported in table 
1.3. 
 
Table 1.3 The types of nanoparticles those are popular for biomedical research. 
Type of 
nanomaterial  
Advantages  Disadvantages  Review article  
Silica 
nanoparticles  
Synthesis in variety of 
shapes and sizes  
Drug loading inside the 
pores of the material  
If coating not stable, 
nanoparticles can cause 
haemolysis  




MRI agents already in 
medicine  
Theranostic application  
If uncoated, can interact 
with proteins and lead to 
opsonisation  




Synthesis in variety of 
shapes and sizes  
Optical properties useful 
for theranostic application  
Ligand attachment 
limited to thiols and 
amines  
(Dykman & 
Khlebtsov 2012)  
Quantum dots  Optical properties useful 
for bioimaging  
Typically made out of 
heavy metals, concerning 
for clearance,  
Toxic for in vivo 
applications 




Drug loading inside the 
material  
Theranostic application  
Low biocompatibility 
and safety, 
Toxic for in vivo 
applications 
(He et al. 2013)  
Liposomes  Biocompatible  
Biodegradable  
Drug loading inside the 
material  
Quick capture by 
reticuloendothelial 
system  
Accumulation in liver 
and spleen  







1.3 Gold Nanoparticles 
Gold nanoparticles hold several advantages over other types of nanoparticles. Their 
physical properties allow them to be used in several applications in biomedical 
applications, and they are easy to synthesize.  Gold nanoparticles also have low toxicity 
that can vary according to their design/way of synthesis.   
 
 
1.3.1 The chemical and physical properties of the gold 
nanoparticles 
Gold nanoparticles have the great advantage of being able to be synthesized in several 
shapes and sizes, such as nanospheres and nanorods. The most commonly used shape for 
drug-delivery research is nanospheres; therefore, this thesis is also focused on using gold 
nanospheres (Gromnicova et al. 2016). The most common size of gold nanoparticles that is 
used for application in biology ranges between 1.5 nm to 50 nm in diameter (Guerrero et 
al. 2010; Sadauskas et al. 2007; Gu et al. 2009; Libutti et al. 2010; Sandhu et al. 2002; 
Prades et al. 2012; Fraga et al. 2013; Yang et al. 2005). The shape and size both are very 
useful determinants of surface properties of the nanoparticle, i.e., how many surface atoms 
might have the ability to react and form a bond. The surface atom reactivity can be 
calculated to determine how many potential ligands can be attached to the gold 
nanoparticle core. For example, gold nanoparticles of 2.2nm diameter have been calculated 
to have about 162 surface atoms (Hostetler et al. 1998). However, Hostetler also calculated 
that not all of them could form bonds. The smaller nanoparticles have a large surface area-
to-volume ratio and might have over 50% of their surface atoms available for reaction 
(reviewed in Gromnicova, 2016). 
Not only their size and shape are easily tuneable, but the gold nanoparticles also have 
many other useful properties, such as their optical and heat-generating properties (used for 
temperature-dependent killing of tumor cells (Zhang et al, 2018)). The optical properties of 
gold nanoparticles are useful for their detection, measuring the gold concentration or 
characterization of nanoparticle size, shape, or ligand coating (Huang et al. 2007). Gold 
nanoparticles (less than 40 nm in diameter) are also able to quench fluorescence 
(Swierczewska et al. 2011), which is a very favourable quality if trying to detect the gold 
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or attached ligands in biological environments. Quenching happens when a gold 
nanoparticle is within a few nanometers of a fluorophore (Dulkeith et al. 2005), when the 
nanoparticle’s surface plasmon resonance (SPR) changes the excitation/emission property 
of the fluorophore, preventing it from emitting light (Kang et al. 2011). 
 
 
1.3.2  Synthesis of gold nanoparticles 
The synthesis of gold nanoparticles is a simple process, the gold nanoparticles are 
produced in a liquid form by the reduction of the gold salt chloroauric acid (H[AuCl4]). 
Chloroauric acid is dissolved by rapid stirring during which a reducing agent is added. This 
procedure produces neutral gold atoms as the Au3+ ions are reduced. There are two general 
methods of doing this to synthesize gold nanoparticles, the Brust-Schiffrin method, and the 
Turkevich method (Brust et al. 1994 and Turkevich et al. 1951). 
In 1951, the Turkevich method was first applied by using sodium citrate as the reducing 
and stabilizing agent, which yields spherical gold nanoparticles suspended in the water of 
about 10-20 nm in diameter. Larger nanoparticles can be produced by using lower 
concentration of sodium citrate (so there is not enough reducing agent to reduce all the 
gold). If there is less sodium citrate used in the reaction, the lower amount of citrate ions 
available for stabilizing the particles causes small particles to aggregate into larger ones 
(until the total surface area of all particles becomes small enough to be covered by the 
existing citrate ions).  
The second method of synthesizing gold nanoparticles is “Brust-Schiffrin”, which was 
discovered by Brust and Schiffrin in the early 1990s. It is used to produce gold 
nanoparticles of about 2-6 nm in diameter that are very stable. The reaction occurs in 
organic liquids that are normally not miscible with water (like toluene). The reducing agent 
used in this method is sodium borohydride, and the stabilizing agent is 
tetraoctylammonium bromide (Templeton et al. 1998; Ackerson et al. 2005). If gold 
nanoparticles are not coated or stabilized with ligands, they will retain their reactive 
abilities (aggregate into bigger nanoparticles). For example, gold nanoparticles can be 
stabilized with sugars (i.e. galactose) along with PEG-amine and insulin, to form a stable 
monolayered protected nanoparticle in a single reaction (Templeton et al. 1998; Ackerson 
et al. 2005). 
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1.3.3 Coating of gold nanoparticles  
It is essential to coat (i.e. with galactose or PEG-amine) the gold nanoparticles used in 
biological systems because if absent, then the gold nanoparticles would aggregate once 
they enter a physiological environment. Aggregation can happen because once the gold 
nanoparticles enter a physiological environment, there is rapid adsorption of proteins from 
the bloodstream to the NP surface, forming a protein coating “the protein corona” (Khan et 
al. 2014). The formation of this protein corona may cause the NPs to aggregate or alter the 
surface chemistry of the NPs. Additionally, protein corona can accelerate blood clearance 
of the NPs and localise them mostly in spleen and liver, which may decrease the dose 
available for accumulation in the brain as well as induce inflammation (Rampado et al, 
2020). Therefore, coating gold nanoparticles with molecules that stabilize them may help 
to maintain the performance and safety of the material (Rampado et al, 2020). 
Gold nanoparticles that transport therapeutics across the BBB need to be stabilized, and 
then a therapeutic cargo attached. Finally, a targeting ligand may be attached to facilitate 
their uptake into target cells or tissues.  
 
 
1.3.4  Ligand place exchange reaction  
One way to attach cargo molecules onto gold glyco-nanoparticles is to use place exchange 
reaction. Since our project involves attaching of DNA onto gold nanoparticles, an 
explanation using DNA follows.  
The reaction occurs when there is an excess of free thiolated DNA molecules added to the 
mixture of thiol-coated gold nanoparticles (figure 1.4). The excess of free thiols react with 
the gold core, where some bind, exchanging for the already attached ligand.  
The place exchange reaction is an easy procedure being very useful for coating gold 
nanoparticles with thiol ligand in a non-reducing environment as reaction is sensitive to the 
reducing environment and may cause to detach the ligands from gold nanoparticles. 
Therefore, this reaction has been used both for coating nanoparticles as well as the release 




Figure 1.4 Mechanism of place exchange reaction. Thiol ssDNA covalently attaches to the gold 
nanoparticle by replacing the galactose ligand. 
 
 
1.3.5 Covalent and non-covalent attachment of ligands 
on the gold nanoparticles 
Gold nanoparticles have been used to deliver several therapeutically useful molecules, such 
as proteins, drugs, or nucleic acids (Daraee et al. 2014).  
Ligands can be attached to spherical gold nanoparticles either covalently or non-
covalently. The covalent bond is stronger than the non-covalent one and thus results in 
more stable ligand attachment. However, sometimes a weaker non-covalent bond is 
preferred as the release of the ligand is faster (Daniel & Astruc 2004).  
The most common and stable covalent linkages to the gold core include a thiol bond and its 
variations (disulfides, dithiols, trithiols, tetrathiols, or xanthates). The strength of the 
covalent bond can be changed by adding several thiols to attach a single ligand to the gold 
core or adding a cyclic thiol at the end group, which increases the strength of the ligand 
(Letsinger et al. 2000).  
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Non-covalent binding of ligands occur via electrostatic interactions, where a charged group 
attracts an oppositely charged molecule. For example, a NH3
+ group on the nanoparticles 




1.3.6 Toxicity of gold nanoparticles 
Gold nanoparticles are generally considered to be non-toxic (Fratoddi et al, 2011). 
However, if taken up and stored inside cells, the catalytic action of NPs can cause 
mitochondrial damage or interact with DNA and/or generate reactive oxygen species 
(ROS) (Manke et al, 2013). It has been suggested that different properties of the gold 
nanoparticles may change their interaction with cells - whether they are taken up or 
become toxic (Fratoddi et al, 2011). The properties that affect the toxicity of gold 
nanoparticles include the size, shape, charge and ligand coating, as well as proteins that 
may attach to nanoparticles (protein corona) from serum. Currently, the most widely 
accepted examples of nanomaterial toxicity are oxidative stress and inflammation. 
Moreover, nanoparticles can also have harmful effects on the autophagy and lysosomal 
pathways, resulting in toxicological consequences. Endocytosis of nanomaterials by both 
phagocytic and non-phagocytic mechanisms mostly ends with lysosome internalization. 
The lysosomes have acidic pH and variety of hydrolytic enzymes (e.g., proteases, 
esterases, phosphatases, nucleases, and lipases) providing an extremely hostile 
environment to degrade all but the most bio persistent nanoparticles. In addition to the 
endo-lysosomal pathway, recent evidence suggests nanoparticles can also induce 
autophagy (Stern and Johnson, 2008). Among the many physiological functions, the 
lysosome, uses autophagy (macroautophagy) pathway to degrade intracellular pathogens, 
damaged organelles and long-lived proteins (Klionsky, 2007). Autophagy induction by 
nanoparticles may be an attempt to degrade what is observed by the cell as foreign or 
abnormal. While the autophagy and endo-lysosomal pathways have the potential to 
influence the disposition of nanoparticles, there is also a growing body of literature 
suggesting that biopersistent nanopartciles can, in turn, negatively impact these pathways 
(Stern and Johnson, 2008).  
Overall, in general gold nanoparticles have been found to be non-toxic in in vitro 
experiments according to many studies. Connor et al, 2005 showed that gold nanoparticles 
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(spheres) of different sizes (4, 12, and 18 nm in diameter) with capping agents (citrate, 
cysteine, glucose, biotin, and cetyltrimethylammonium bromide) were found to be non-
toxic based on the MTT assay on human leukemia cell line. Similar results were showed 
for gold nanoparticles (spheres, 3.5 nm in diameter) on immune system cell lines by 
Shukla et al, 2005, where gold nanoparticles entered the cell by endocytosis, did not induce 
any toxicity, and reduced the level of reactive oxygen species. In contrast to these results, 
other groups have found that gold nanoparticles are “toxic”. For example, Goodman et al, 
2004 found that cationic 2 nm gold nanoparticles are toxic (at certain doses). Interestingly, 
the same gold nanoparticles with a negatively charged surface were found to be non-toxic 
used at the same concentration in the same cell line. Pan et al, 2009 also showed that 
1.4nm gold nanoparticles triggered necrosis, mitochondrial damage, and induced an 
oxidative stress on number of examined cell lines (Human colon carcinoma cells, HeLa, 
Human lung carcinoma cells, Human liver carcinoma, baby hamster kidney cells, Human 
dermal fibroblast and many more). However, Pan et al, 2009 found no evidence for cellular 
damage for 15nm gold nanoparticles of the same surface group. The study highlights, there 
may be a possible size-dependent toxicity of gold nanoparticles (Pan et al. 2009). In 
particular, gold nanoparticles smaller than 2 nm in diameter show evidence of chemical 
reactivity that does not occur at larger sizes (Turner et al. 2008).  
For in vivo toxicity there is a real need to investigate the long term exposure of gold 
nanoparticles before any potential therapeutic applications. 
The available literature reports, both in vitro and in vivo, vary widely in their methods and 
conclusions (Ostrowski et al. 2009). Many reports indicate that gold nanoparticles are 
nontoxic; however, others contradict this finding. The conflicting cytotoxicity results can 
arise from the variability of the different cell lines used, different toxicity assays or due to 
different chemical/physical properties of nanoparticles. For example, cytotoxicity results 
can vary with the different cell lines i.e. citrate coated 13nm gold nanoparticles were found 
to be toxic to a human carcinoma lung cell line but non-toxic to the human liver carcinoma 







1.3.7 Gold nanoparticles clearance 
According to FDA guidelines, pharmaceutical drugs should be eliminated via metabolism 
or excretion processes after they enter the body as it reduces toxicity and prevents drug 
accumulation. Similar to pharmaceutical drugs, nanoparticles should be designed to be 
eliminated in the body. Many studies have found that the nanoparticles with hydrodynamic 
diameters ≤5.5 nm are generally to be excreted from the rat body by the renal route (Choi 
et al. 2007). Since the majority of the gold nanoparticles used in studies are larger than the 
renal filtration cut-off, the gold nanoparticles are not always excreted in urine, instead they 
were found to be eliminated from the blood by the reticuloendothelial system  and 
therefore to accumulate in the spleen and liver (Sadauskas, et al. 2007). 
 
1.3.8 Gold nanoparticles in clinical trials 
FDA has approved few gold nanoparticle based technologies for diagnostic and therapeutic 
purposes in medicine.  
- Clinical trials carried out by Astra Zeneca in partnership with Cytimmune; on gold 
nanoparticle-based cancer treatment. Aurimune (CYT-6091) (pegylated colloidal gold 
particles) was used as a vehicle to deliver the recombinant human tumor necrosis factor 
alpha (rhTNF) into tumors, which disrupted the blood vessels, enabling chemotherapeutic 
drugs to penetrate the tumor and damage the cancer cells. Safe delivery of highly effective 
doses of rhTNF to tumor cells was observed (Libutti et al. 2010).  
- AuroLase® (silica-gold nanoshells coated with (poly)ethylene glycol (PEG)) 
nanoparticles are also in clinical trials for localized therapy for the treatment of primary or 
metastatic lung tumors (NCT01679470) (Anselmo et al. 2016). A currently active trial uses 
AuroLase® as an imaging technology during focal ablation of prostate tissue using 
nanoparticle-directed laser irradiation. Since no active drug is used in this approach, 
AuroLase® is activated externally at the target site, thus avoiding any toxicity towards the 
normal cells (Anselmo et al. 2016). 
- Gold nanoparticles conjugating with spherical nucleic acid formulation (composed 
of siRNAs) targeting the Bcl-2-like protein 12 (BCL2L12) sequence that has potential 
antineoplastic activity are in clinical trials for the safety evaluation. (Kharlamov et al. 
2015). Kharlamov et al. 2015 studied the safety and feasibility of two delivery techniques 
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for gold nanoparticles for the treatment of atherosclerosis. Results obtained in the trial 
suggested that gold nanoparticles are associated with a significant regression of coronary 
atherosclerosis and an acceptable level of safety for clinical practice. 
- Another gold nanoparticle based therapy in clinical trial is to use gold nanoparticles 
for breath analysis with a nanosensor array for identifying gastric diseases. It has been 
suggested that the nanosensor array could provide the missing non-invasive screening tool 
to distinguish gastric cancer and related precancerous lesions (Xu et al . 2013). 
 
 
1.3.9 How nanoparticles can cross the BBB 
As previously mentioned, many therapeutic drugs are not able to reach the brain. Gold 
nanoparticles could potentially enhance drug delivery as they can cross the BBB via 
intracellular traffic pathways (Sarin et al. 2008). Different pathways affect the delivery of 
gold nanoparticles to the different intracellular compartments and therefore, may affect 
their delivery and ultimate destination. Intracellular localization detected by transmission 
electron microscopy is the first tool to analyse the transport mechanism. Gold 
nanoparticles have been observed in the cytosol, vesicles, or in the nucleus of the brain 
endothelial cells (Gromnicova et al, 2016). The different ways NPs can cross the BBB are 
described below. 
 
1.3.9.1 Crossing the BBB without functionalization  
Nearly all nanomaterials are BBB impermeable, however, gold nanoparticles have been 
shown to reach the brain and accumulate in neurons even in the absence of any specific 
functionalization (Masserini, 2013). Gromnicova et al, 2014 showed a rapid movement 
(within 10 mins) of <5nm glyco-nanoparticles into all neuronal cells within rat cortex. 
Such movement was too quick to be employed by diffusion via intercellular spaces. Hence, 
NPs may possibly cross BBB using active transport. 
 
1.3.9.2 Adsorptive-mediated transcytosis 
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The concept of adsorptive-mediated transcytosis involves binding of cationic proteins to 
endothelial cell surface and crossing the BBB. The mechanism involves functionalization 
of the surface of the gold nanoparticles in a way that will allow electrostatic interaction 
with the luminal surface of the BBB. Since endothelial cells have negative (due to the 
sulphated glycocalyx) or positive charges (some cells or some regions in cells have 
positive charge due to existence of positive proteins), this interaction can be promoted by 
conferring a positive and/or negative charge to the gold nanoparticles surface. 
 
1.3.9.3 Receptor mediated transcytosis 
Transcytosis is the process by which extracellular cargo is internalized at the plasma 
membrane (the apical side) of the cell and is transported via vesicular transport to the basal 
side (see section 1.3). The transcytosis transport mechanism of macromolecules relies on 
the presence of specific receptors on the luminal surface of brain endothelial cells. For 
example, insulin, transferrin, and apolipoproteins are some of the proteins that reach the 
brain through receptor-mediated transcytosis. 
 
 
1.3.10 Exocytosis of nanoparticles  
Nanoparticles administered into the body are eventually cleared by organs such as the 
kidney, liver or spleen. However, they can remain in the organs for a long time if taken up 
by macrophages (Oh et al, 2014), thus increasing the likelihood of acute or chronic 
toxicity.  
Therefore, it is important to evaluate exocytosis (from brain and other organs) of gold 
nanoparticles for biosafety purposes. Previous research has shown that exocytosis may 
depend on the incubation time of nanoparticles with cells. For example, Bartczak et al, 
2012 showed that 14nm peptide coated gold nanoparticles exhibited a faster rate of 






1.3.11 Detection of gold nanoparticles in vitro and 
in tissues 
Depending on experimental design, there are different ways to detect and quantify gold 
NPs in biological applications. Two of the methods for analysis of gold NPs uptake used in 
this project included electron microscopy and inductively coupled plasma mass 
spectrometry (ICP-MS). 
 
1.3.11.1 Electron microscopy 
The most common method for imaging, detecting and quantifying gold NPs is transmission 
electron microscopy (TEM). Gold NPs can be detected on the cells’ surface by scanning 
electron microscopy (SEM) or inside the cells and their intracellular compartments by 
TEM. Gold NPs smaller the 10nm may not be visible by standard SEM or TEM, but 
methods such as silver enhancement can be used (deposition of silver atoms onto gold NPs 
increase the particle size to up to ~20 nm in diameter).   
There are several advantages of using TEM for analysis of the uptake of gold NPs into the 
cells and tissues. The data produced can be both quantitative and qualitative. Moreover, 
once the sample has been processed for electron microscopy, it can be repeatedly analysed. 
There are also some disadvantages of using electron microscopy. It is an expensive and 
time-consuming technique. Moreover, imaging of real-time events is not possible due to 
the nature of the technique that requires thoroughly dehydrated sample for observations. 
 
1.3.11.2 Inductively-coupled plasma mass spectrometry (ICP-
MS) 
ICP-MS is a technique that is used for quick and accurate measurements (lower limit of 
sensitivity <1 pg/ml) of metals in experimental samples. In terms of detecting gold NPs, 
the method can be used to measure number of nanoparticles in biological cultures (cells 
with gold NPs) as the gold concentration is directly related to the number of nanoparticles 
in the cell culture.   
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1.4 Gold nanoparticles to transport oligonucleotide-based 
therapeutics for CNS drug delivery 
Short fragments of nucleic acids, such as CRISPR/Cas9 system (gene editing) and 
antisense oligonucleotides (ASOs) (gene silencing) provide promising approaches to treat 
neurodegenerative diseases. By direct intervention at the mRNA level, they may bind to a 
mutated gene and reduce production of pathogenic proteins (Sah & Aronin, 2011). Their 
conceptual simplicity, the possibility of rational design, relatively inexpensive cost, and 
developments in the sequencing of the human genome has led to use oligonucleoties as 
therapeutic agents or as tools to study gene function (Verma, 2018).  
Over the last few years, there has been remarkable progress in the development of 
oligonucleotide therapeutics. Currently, oligonucleotide-based therapeutics form the third 
major drug development platform (Sah & Aronin, 2011), mainly focusing on modulating 
gene expression by targeting RNA or the genome itself. Oligonucleotides can be used to 
manipulate thousands of messenger-RNAs (mRNA) that play an essential role in cellular 
functions.  
Antisense oligonucleotides can alter mRNA function through several distinct mechanisms, 
making them a diverse tool (Dias & Stein, 2002). They can be used to restore protein 
expression, reduce the expression of a toxic protein, or modify mutant proteins to reduce 
their toxicity. Antisense oligonucleotides can be synthesized as small as 8 – 30 nucleotides 
and easily hybridized to a complementary sequence of gene of interest (Choung et al., 
2006) (i.e., in treating HD, these oligonucleotide strands would be complementary to the 
mRNA that codes for the mutant Huntington protein) (Sah & Aronin, 2011). 
Oligonucleotides are specifically designed to modulate the transfer of genetic information 
to protein i.e. oligonucleotides with a complementary sequence can hybridize to a specific 
mRNA and can inhibit its expression inducing a blockade in the transfer of genetic 
information from DNA to protein (Verma, 2018) 
 Oligonucleotides can be divided into two forms according to their mode of action:  
• The RNase H-dependent oligonucleotides, which work by inducing the 
degradation of mRNA 
• The steric-blocker oligonucleotides, which work by physically preventing 
or inhibiting the progression of splicing or the translational machinery. 
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This way, the information in the DNA that codes for the harmful protein causing 
the disease does not pass onto the ribosome, and the harmful mutated protein is 
never formed (Rader et al., 2014). 
For neurodegenerative disorders such as Huntington disease, antisense oligonucleotide 
therapy has moved from preclinical to the clinical stage, facilitated by the remarkable 
distribution and cellular uptake of antisense oligonucleotides when delivered into the brain 
(Sah & Aronin, 2011). However, since Huntington disease is a chronic disease, long-term 
and repeated administration is required to provide sustained benefits.  
An alternative to antisense oligonucleotides is CRISPR/Cas9 system. CRIPSR/Cas9 is a 
gene editing therapeutic approach based on natural mechanism of editing the target-
specific DNA sequence of the genome by using three molecules; nuclease (Cas9), 
responsible for cleavage of the double-strand DNA; an RNA guide (short sequence), which 
guides the complex to the target; and the target DNA. The mechanism involves designing a 
stretch of 20nt base pairs (target DNA) that matches the gene that needs to be edited. An 
RNA molecule complementary to those 20nt base pairs is constructed (guide RNA).Then 
the protein [Cas9] will cut the DNA sequence of interest at a specific site (Cong et al, 
2013). Once the DNA is cut, the cell's natural repair mechanisms kick in and work to 
introduce mutations or other changes to the genome. CRIPSR/Cas9 has a potential to 
achieve the same benefits antisense oligonucleotides in treatment of Huntington disease 
but with a lasting effect, since it permanently inactivates the defective gene (Heidenreich & 
Zhang, 2016). Therefore, CRISPR/Cas9 can treat other single gene defect disorders 
because it involves gene editing which changes the sequence of DNA (by inserting a cut or 
break in the DNA). This changes the message the gene is giving and “tricks” a cell's 
natural DNA repair mechanisms into introducing therapeutic changes (Cong et al, 2013). 
 
 
1.4.1 Current development of gene therapy 
Advances in gene therapy in recent years have led to numerous studies investigating the 
therapeutic potential of oligonucleotides in various in vitro cell models, animal disease 
models, and in human clinical trials (Verma, 2018). Gene therapy is emerging as 
potentially beneficial treatment for several diseases such as tumors, cancer anaemia, 
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rheumatoid arthritis, cardiovascular diseases, HIV/AIDS, cystic fibrosis, diabetes mellitus 
and obesity, and renal diseases (Verma, 2018).  
In 2013 in the US, the food and drug administration (FDA) approved two antisense 
oligonucleotide drugs, lomitapide, and mipomersen, for the treatment of familial 
hypercholesterolemia. Lomitapide and mipomersen antisense oligonucleotide drugs work 
by targeting expression of the gene apolipoprotein-β, which promotes lowering the 
cholesterol (Rader et al., 2014). 
A pharmaceutical company Isis pharmaceuticals has been successful in treating an eye 
disease associated with AIDS with their antisense drug, Vitravene©. The company is 
currently working on $9.9 million project to engineer an antisense drug for Huntington 
disease. Besides that, they have made promising advances in scientific trials of antisense 
technology to treat other conditions including high cholesterol and Parkinson’s disease 
(ISIS pharmaceuticals, 2010). 
 
 
1.4.2 Challenges for delivery of naked oligonucleotides 
into the brain 
Delivery of oligonucleotides across the BBB, for diseases like Huntington’s disease, is 
challenging because the therapeutics cannot simply enter the brain. Therefore, our research 
has mainly focused on solving the problem of delivering therapeutic oligonucleotides into 
the CNS by not having to disrupt the BBB. The novel approach used for this project 
consists of using ~2nm gold nanoparticles as a nanocarrier to deliver oligonucleotides 
(covalently attached) into the brain. 
 
 
1.4.3 Thiol-modified oligonucleotides 
Thiol-modified DNA oligonucleotides have been used extensively, not only on gold 
nanoparticles. They can be used for reaction with a broad array of activated accepting 
groups, such as maleimide, cysteines in proteins and are suitable for binding to gold 
nanoparticles. Next, they have characteristics that make them useful as probes for detection 
of target molecules. For example, the infrared dye IRDye® 750 (Li-Cor) widely used in 
microscopy, is available in either NHS ester (amino groups with activated N-
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hydroxysuccinimide esters) or maleimide form. Horseradish peroxidase (HRP) can be also 
used as a modifier of oligonucleotides in several target detection applications, such as in 
situ hybridization and immunoassays. Most importantly, owing to the strong affinity of 
thiol groups for gold surfaces, thiol oligonucleotides are extensively used for the 
preparation of functionalized gold nanoparticles (Zimmermann et al. 2010). 
Lastly, thiol-modified oligonucleotides can be easily synthesised by incorporating the thiol 
modification at either the 5′- end or the 3′-end of the oligonucleotide.  
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1.5 Aim of thesis 
As mentioned previously, effective drug delivery to the brain is challenging due to the 
existence of the BBB. As new therapeutic molecules emerge with the potential to treat 
brain disorders, there is a need for a therapeutic nanocarrier that can be transported into the 
brain while retaining its therapeutic cargo. Gene editing or silencing through nucleic acids 
is currently one of the most promising approaches to treat neurodegenerative diseases. 
However, securing consistent delivery into the CNS presents several challenges. One 
approach is to use gold nanoparticles to deliver therapeutic oligonucleotides into the brain 
parenchyma. Previous work in our group (Gromnicova et al., 2014) showed that gold 
glyco-nanoparticles of <5 nm in diameter can enter rat brain and have the potential to act 
as a delivery system of oligonucleotide therapeutics into the brain.  
Hence, gold glyco-nanoparticles of <5 nm in diameter were investigated as a delivery 
system of oligonucleotides into the brain.  
 
Aims of the following chapters include: 
Chapter 3:  To determine a suitable methodology of attaching 20nt and 40nt 
oligonucleotides to the ~5nm gold glyco-nanoparticles via place exchange reaction and to 
assess cell uptake efficiency of the DNA coated nanoparticles using 2D cellular models of 
the BBB. 
Chapter 4- To isolate NP-DNA-40ds with different numbers of 40nt DNA molecules 
attached to each nanoparticle using FPLC and to assess uptake efficiency of the different 
sized NP-DNA-40ds using the 3D co-culture model of the BBB. 
Chapter 5- To assess nanoparticles intracellular localisation in brain, kidney, liver and 
spleen using transmission electron microscopy and to determine overall bodily distribution 
by measuring gold concentration in each organ using ICP/MS of the different sized NP-
DNA-40ds when injected in rats intravenously and intracarotidly (in vivo).  
Chapter 6 – To quantify how much DNA was transported across the brain endothelial 
cells in 2D cellular models of the BBB  
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2  MATERIAL AND METHODS 
2.1 Nanoparticle associated methods 
 
2.1.1 Synthesis of gold glyconanoparticles  
Gold glyconanoparticles were obtained from Midatech Pharma Plc. They were synthesised 
using a modified Brust-Schriffrin method. The procedure consisted of mixing gold salt and 
SH-C2 -alpha-galactose ligands in water and methanol at a specific molar ratio (not 
known; confidential synthesis protocol by Midatech). The addition of reducing agent, 
sodium borohydride, to the mixture resulted in instant formation of small gold 
nanoparticles. Gold nanoparticles were dissolved in water and characterized by Midatech 
using HPLC (high-performance lipid chromatography) and DLS (dynamic light scattering) 
on a Nano ZSP Zetasizer (Malvern instruments). The nanoparticles have gold core of 2nm 
in diameter, determined by transmission electron microscopy, and the size of the glycol-
nanoparticles is 3.63 ± 1.09 nm (mean ± SD) measured by DLS.  These nanoparticles have 
approximately 100 gold atoms in the core and 40 covalently bound C2-galactose molecules 
on the outside, attached by disulphide bonds, as determined by  molecular mass of the gold 
core (~20,000) and physical size. 
Two batches of galactose-coated gold nanoparticles were used in this work (size by DLS is 
3.63+/- 1.09 nm (mean SD)):  
 Batch A (100% C2aGalNP)- 2.33 mg/ml – batch used for the (unfractionated) in 
vitro 2D transfer assay; NP-DNA-20ss vs NP-DNA-20ds and NP-DNA-20ds vs NP-
DNA-40ds (in chapter 3 respectively). 
 
 Batch B (100% C2aGalNP)- 5mg/ml – batch used to prepare one large batch of 
(fractionated) NP-DNA-40LO and NP-DNA-40HI used for in vivo experiments, 3D 
co culture transfer assays and qPCR quantification (in chapter 4, 5 and 6 
respectively). 
*No batch variability was observed. 




2.1.2 Preparation and characterisation DNA-coated gold 
glyconanoparticles  
2.1.2.1  DNA Sequences 
For the sequence of DNA with 5’ C6 spacer with thiol group we selected a 20 nt DNA 
sequence. The selected DNA sequence was derived from a GFP gene (green fluorescence 
protein), obtained from a plasmid of Neisseria gonorrhoeae (pCmGFP) (GenBank: 
FJ172221.1). Oligonucleotide sequence to make; 
1) NP-DNA-20ss and NP-DNA-20ds 
 20nt thiol-DNA – ssDNA; 
5’ Thiol-C6- AAT ATC GCG GAC AGA AGA CG 3’ (Sigma)  
 
 20nt DNA complementary to thiol-DNA – to make dsDNA; 
5’ CG TCT TCT GTC CGC GAT ATT  3’  (Sigma) 
5’ HS-C6-AAT ATC GCG GAC AGA AGA CG        3’ 
3’       TTA TAG CGC CTG TCT TCT GC        5’   
 
 
2) NP-DNA-20ds with biotin tag 
20nt DNA complementary to thiol-DNA with Biotin for EMSA analysis 
5’ Biotin - CG TCT TCT GTC CGC GAT ATT  3’  (Sigma) 
5’ HS-C6-AAT ATC GCG GAC AGA AGA CG        3’ 
















NP-DNA-20ds with Biotin  
 
 




 5’ HS-C6-AAT ATC GCG GAC AGA AGA CG 3’ (Sigma) = 20nt thiol-DNA 
strand 1 
 5’ – AAAAGCTCTGCCTTGGTTTCCGTCTTCTGTCCGCGATATT-3’ 
(Sigma) = 40nt DNA strand 2 
 5’- GAAACCAAGGCAGAGCTTTT- 3’ (Sigma) = 20nt DNA for extension on 
strand 1 
5’ HS-C6–AATATCGCGGACAGAAGACGGAAACCAAGGCAGAGCTTTT  3’ 
    3’   TTATAGCGCCTGTCTTCTGCCTTTGGTTCCGTCTCGAAAA  5’ 
 
4) NP-DNA-40ds with biotin tag 
 5’- GAAACCAAGGCAGAGCTTTT---Biotin 3’ (Sigma) = 20nt DNA for 
extension on strand 1 with Biotin for EMSA analysis. 
5’ HS-C6–AATATCGCGGACAGAAGACGGAAACCAAGGCAGAGCTTTT-Biotin 3’ 








NP-DNA-40ds with Biotin 
 
Figure 2.2 Extension of the NP-DNA-20ss by the addition of 40nt complimentary DNA to make 
NP-DNA-40ds (illustrative images). 
 
 
2.1.2.2  Reduction of thiolated DNA  
The purchased thiol DNA from Sigma (Poole, Dorset) came protected because the thiol 
bonds are strong nucleophiles, and if they are unprotected, they spontaneously form 
disulphides in neutral aqueous solution. 
Tris(2-carboxyethyl)phosphine (TCEP) was used to reduce the thiol DNA to yield free 
thiol.  Molar ratio of 1 nmol of DNA to 1.25 nmol of TCEP (made up in 0.1M tris/HCL 
(pH 7.5)) was used and mixture incubated at RT for 4 hours. 
 
The procedure of the reaction was as follows: 
 Prepared 1mM TCEP – 2.8mg TCEP added in 10 ml of 0.1M tris/HCL (pH 7.5) 
 Thiol DNA had 376.5 nmol DNA in powdered form.  
 Reaction performed at 1 : 1.25 molar ratio;  
          376.5 nmol DNA : 470.625 nmol TECP 
                     10mM (x106) …………….. 1 Litre (TCEP) 
                        470.625 nmol ..………….. 4.70625 (x10-5) 
                                           = 47 µl /2 (TCEP breaks 2 molecules) 
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                          = 23.5 µl of 1mM TCEP used to reduce 376.5 nmol of Thiol DNA 
 Incubated at room temperature for 4 hours. 
 Added 26.5 µl 0.1M tris/HCL (pH 7.5) to make up final volume of 50 µl. (Note: 
end volume of 0.1M tris/HCL (pH 7.5) can be adjusted to make up final desired 
volume aliquot of Thiol DNA). 
 
 
2.1.2.3 Ligand place-exchange reaction to prepare DNA coated gold 
nanoparticles  
 
20 nucleotide DNA-coated nanoparticles (NP-DNA-20) 
To prepare 20 nucleotide DNA-bound nanoparticles, galactose-coated gold nanoparticles 
were mixed with 20nt thiol DNA to make NP-DNA-20ss at a molar ratio of 1 
(nanoparticles) to 14 (Thiol DNA). The place exchange reaction occurred over 2 days at 37 
°C. The 0.5mL reaction tube was kept in a storage container flushed and sealed with 
nitrogen gas to prevent spontaneous oxidation between free DNA thiols. 
 
The step-by-step procedure for ligand place-exchange reaction:  
 14:1 molar ratio of DNA : nanoparticles. Each Thiol DNA aliquot contained 1.4 
nmol DNA in a 10 µl volume. 
 Nanoparticles required – 0.1 nmol for 1.4 nmol DNA 
 Stock galactose nanoparticles = 2.33 mg/ml. molecular weight = 20,300 
 For place exchange reaction: 0.1 x10-9 x 20,300 = 2.03 x10-6 g nanoparticles 
                                            = 2.03 x 10-6 / 2.33 (mg/ml) = 0.87 µl stock nanoparticles 
 Added 0.87 µl nanoparticles to 1.4 nmol Thiol DNA aliquot, flushed with nitrogen 
gas in sealed container and incubated at 37 °C for 48 hours. 
 
20nt dsDNA-coated gold glyconanoparticles  
To make NP-DNA-20ds, equimolar amount of 20nt DNA complementary to the thiol-DNA 
(with or without biotin depending on the nature of the experiment) was added. Biotinylated 
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complementary DNA was used for EMSA analysis. Nanoparticle transport assay required 
the com plementary DNA to be un-biotinylated. 
After the reaction to exchange galactose with DNA was finished, equimolar amount (1.4 
nmol) of 20nt complementary DNA (dissolved in nuclease-free water) to thiol-DNA was 
added. The pure DNA comes in powder form and nuclease free water is added to liquefy. 
 
40 nucleotide DNA-coated nanoparticles (NP-DNA-40) 
40 nucleotide DNA-coated nanoparticles (NP-DNA-40) were prepared as described above, 
using place exchange reaction to attach 20nt thiol DNA onto gold nanoparticles first. After 
the reaction, a 40nt DNA (strand 2) and 20nt ssDNA DNA (for an extension on strand 1) 
was added to NP-DNA-20ss at an equal molar ratio to thiol-DNA. The mixture was 
incubated at room temperature for 30 mins for hybridisation to take place (figure 2.2). 
 
Step-by-step procedure of the elongation of 20nt DNA-coated nanoparticles to form 40nt 
DNA-coated nanoparticles: 
 Place exchange reaction was performed between nanoparticles and Thiol 20nt DNA 
for 48 hours (refer to chapter 2.1.4.1) 
 After the reaction, equimolar amount (1.4 nmol) of 40nt DNA and (1.4 nmol) 
extended 20nt ssDNA was added to NP-DNA-20ss. 




2.1.3 FPLC of 40nt DNA-coated nanoparticles 
A large batch of NP-DNA-40ds was fractionated to prepare nanoparticles with different 
densities of DNA molecules attached (NP-DNA-40LO and NP-DNA-40HI). These fractions 
were used for all in vitro 3D BBB transfer assay and in vivo experiments.  
9.14 mg (1386 nmol) of reduced thiol-DNA was added to 2mg (99 nmol) of galactose-
coated nanoparticles (batch B, Midatech Pharma), and the mixture was incubated at 37 °C 
for 48 hours.  
The nanoparticles were analysed on FPLC ÄKTA pure (GE Healthcare) and separated 
using Superdex 200 10/300 GL column (with PBS as elution solvent), a gel filtration 
and/or Size-exclusion chromatography (SEC).  The elution volume for all fractions was set 
at 0.5ml at flow rate of 0.4 ml/min and UV wavelength of 260nm. The fraction (described 
in figure 2.3a) of 20nt DNA bound nanoparticles eluting out at fraction-15, 16, 17 were 
pooled together (illustrated in figure 2.3b) to prepare formulation of nanoparticles with 
High DNA ratio bound nanoparticles (NP-DNA-40HI) by adding equimolar 40nt ssDNA 
(strand 2) and 20nt extension ssDNA onto strand 1 (Section 2.1.2.1 for DNA sequences). 
Fractions eluting out at fraction-19, 20, 21 were pooled together to prepare formulation of 
nanoparticles with Low DNA ratio bound nanoparticles (NP-DNA-40LO) by adding 
equimolar 40nt ssDNA (strand 2 ) and 20nt extension ssDNA onto strand 1. The rest of the 
fractions eluting out much further down the column were identified as excess DNA dimer 







Figure 2.3 Representative fractions eluting at different times. b) Illustrating which fractions were 
pooled to make NP-DNA-40LO and NP-DNA-40HI. 
 
 
2.1.4 Analysis of gold concentration by spectrophotometric 
gold assay 
Formulations prepared and purified on FPLC of NP-DNA-40LO and NP-DNA-40HI were 
measured for their gold concentration against a standard (Gold standards for AAS 1000 
mg/ml, Sigma). 5 different gold standard concentrations were used: 0.857 mg/ml, 1.75 
mg/ml, 2.5 mg/ml, 5 mg/ml and 10 mg/ml.  
The assay was performed in a 96 well plate, with a total volume of 200μl in each well. In 
each well, 10μl of sample, 10μl H2O and 30μl of 100% freshly prepared aqua regia (kept 
on ice) were added. The liquids were then mixed by gentle tapping and left to incubate for 
a 1 min. Next, 150μl of 2M NaBr was added. The absorbance was read on a plate reader 
using OPTIMA FluoSTAR, at 390 nm.  
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2.1.5 Electrophoretic mobility shift assay (EMSA) to analyse 
DNA bound nanoparticles 
2.1.5.1  Sample preparation 
 
- NP-DNA-20ds with Biotin tag 
Complementary biotinylated DNA was hybridised with NP-DNA-20ss to form NP-DNA-
20ds in order to perform EMSA detection. Molar ratio of 1nmol of NP-DNA-20ss to 1.15 
nmol of 20nt biotinylated ssDNA (complementary to thiol DNA) (1 : 1.15) was used. The 
sample mixture was adjusted to pH ~ 8 by adding 10X TBE buffer, leaving the final 
concentration of the TBE buffer 0.5X (pH 8.3) in the sample mixture. The mixture was 
incubated for 30 min at room temperature for the hybridization to take place.  
 
- NP-DNA-40ds with Biotin tag 
40nt DNA (which has its first 20nt complementary to the thiol DNA bound on to 
nanoparticles) and a biotin DNA (complementary to the last 20nt of 40nt DNA), was added 
in the mixture of NP-DNA-20ss to hybridize the ssDNA bound on nanoparticles and extend 
the 20nt DNA to a 40nt long dsDNA. The samples were incubated for 30 mins at room 
temperature to permit hybridization.  Later, samples were x100 diluted in water (purite; 
high performance water purification system is needed as EMSA is highly sensitive 
technique). 
After preparation of NP-DNA-20ds-Biotin and NP-DNA-40ds-Biotin, samples were 
prepared to run on gel.  
 
2.1.5.2 Preparation of Gel 
Samples of NP-DNA-20ds-Biotin were run on a 6% polyacrylamide gel whereas, a sample 
consisting of NP-DNA-40ds-Biotin were run on a 5% polyacrylamide gel. Gels were 
prepared as indicated: 
5% Acrylamide gel: 3.3ml 30% acrylamide/Bis Solution (37.5:1) (Bio-Rad), 1ml 10X 
TBE, 15.7ml H2O, 13mg ammonium persulfate (APS), 40 µl tetramethylethylenediamine 
(TEMED). Overall volume was 20 ml, which is enough to make two gels. 
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6% Acrylamide gel: 4ml 30% acrylamide/Bis Solution (37.5:1), 1ml 10X TBE, 15ml 
H2O, 13mg ammonium persulfate (APS), 40 µl tetramethylethylenediamine (TEMED). 
Overall volume is 20 ml, which is enough to make two gels. 
 
The gel was pre-run in 0.5X TBE at 85 V for 1hr. The sample (20μl in each gel well) was 
loaded on the gel using the following mixture: 1 μl DNA-bound nanoparticle stock, 6 μl 
5X TBE, 13 μl Water, 5 μl loading dye (6X, Fermentas). The gel was run in 0.5X TBE at 
90V for 1hr and 10 mins for NP-DNA-20ds-Biotin and 1hr and 20 mins for NP-DNA-40ds-
Biotin. The gel was transferred onto a nylon membrane Amersham Hybond N+ (GE 
Healthcare) at 100 V for 1hr and 15 mins in 0.5X TBE at 4° C. DNA was then cross-linked 
onto the membrane with UV (120mJ/cm2) and developed using the manufacturer’s 
instructions of chemiluminescent nucleic acid detection module kit (Thermofisher). 
GelDoc system was used to photograph the membrane.  
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2.2 Cell culture methods 
Table 2.1 Cell cultures. 
Cell line  
Brain endothelial 
cell line  
 
Abbreviation - hCMEC/D3 
Source/supplier - Weksler et al. 2005 
Passage used - 26-30 
 
Medium: modified EBM-2 (Lonza) - contained 0.025% VEGF, 
IGF and EGF; 0.1% bFGF, 0.1% (v/v) rhFGF, 0.1% (v/v) 
gentamycin, 0.1% (v/v) ascorbic acid, 0.04% (v/v) hydrocortisone. 
The amount of serum was reduced to 2.5% (v/v) of foetal bovine 
serum. 
Maintenance - Frozen hCMEC/D3 cells (p25) cells thawed and 
grown on collagen coated (type I from calf skin (Sigma, 
Gillingham, UK)) T-25 culture flask with EBM-2 MV medium 
(changed every 2-3 days).  The cell’s medium was kept to surface 
area ratio at 1ml per 5 cm2. 
The cells were split when 90% confluent, and once confluent, they 
were washed X2 with HBSS and trypsinized with 0.05% trypsin-
EDTA InvitrogenTM Life Technologies) for 3-5 mins. The cells 
were seeded according to the seeding density of cells/cm2. 
At all times, the cells were incubated at 37 °C. All cultures were 






Abbreviation – hA  
Source/supplier - ScienCell 
Passage used – 2-7 
 
Medium - Astrocyte medium (ScienCell) – supplemented 
according to manufacturer’s instructions with FBS (2%), astrocyte 
growth supplement (1%), and Penicillin/streptomycin solution 
(1%). 
Maintenance – Frozen hA cells (passage 2) thawed and grown on 
collagen coated (type one from calf skin) T-25 culture flask with 
astrocyte media (changed every 2 days). The cell medium was kept 
to surface area ratio at 1ml per 5 cm2. 
The cells were split when 70-80% confluent and once confluent, 
they were washed X2 with HBSS and trypsinized with 0.05% 
trypsin-EDTA (InvitrogenTM Life Technologies) for less than 3-5 
mins. The split cells were transferred into T-75 flasks to grow more 
cells. 
At all times, the cells were incubated at 37 °C. All cultures were 





2.2.2 2D uptake and transport assay of DNA-coated gold 
nanoparticles in brain endothelial cells 
 
A 2D nanoparticle transport assay was performed on hCMEC/D3 cells to compare the 
uptake and transport of nanoparticles with oligonucleotide cargos as follows: 
- NP-DNA-20ss compared with NP-DNA-20ds transport assay 
- NP-DNA-20ds compared with NP-DNA-40ds transport assay 
For all 2D nanoparticle uptake and transport assays, hCMEC/D3 cells (of passages 
between 26 and 30) were seeded on collagen coated 0.4 µm polyester membrane trans-well 
inserts (Corning Costar). The trans-well inserts used were either 6.5 mm (seeding density 
20,000 cells/insert) or 12 mm (seeding density 70,000 cell/insert). The hCMEC/D3 cells 
were grown until confluent (2-3 days). The trans-well system consists of the top chamber 
(inside of trans-well insert), in which the cells grow and bottom chamber (well plate) 
volume with culture medium. The medium applied in each chamber depended on size of 
trans-wells used, which is summarised in table 2.2. 
 
Table 2.2 Recommended trans-well inserts medium volumes. 
Trans-well 
insert (diameter) 
Multiple well plate 
(to place inserts) 
Medium added in 
top chamber 
Medium added in 
bottom chamber 
6.5mm 24 well 0.1 ml 0.5 ml 
12mm 12 well 0.5 ml 1.5 ml 
 
The nanoparticles at a final concentration 8 μg/ml were applied to the upper chamber (of 
insert) in EBM-2 MV medium and incubated at 37 °C for 3 hours. After the incubation, 
both chambers were washed 3x in 0.5ml Hank's Balanced Salt Solution (HBSS). The cells 
were fixed for 1 hr at room temperature in 2.5% glutaraldehyde in 0.1M PB (Sörensons 
phosphate buffer). The fixative was removed and the chambers were washed 3X in PBS 
(phosphate buffer saline) and stored in 0.1M PB at 4 °C (summarized in figure 2.3). The 






Figure 2.4 Nanoparticle uptake and transport assay. 
 
 
2.2.3 3-dimensional co-cultures for uptake and transport 
assay of DNA-coated nanoparticles  
3-dimensional co-cultures of human brain endothelial (hCMEC/D3) cells and human 
astrocytes (hA) were used for nanoparticle uptake and transport assays.  Astrocytes of 1.5 
x106/ml were seeded into a collagen gel solution.  The collagen gel solution was prepared 
using 80% (v/v) rat type I collagen with a stock concentration of 2 mg/ml, 10% 10x MEM, 
10% human astrocyte cell suspension in astrocyte medium, and plated in a 24 well plate 
(500μl/well). Before adding the cell suspension to the collagen and 10x MEM solution, 5M 
NaOH was added drop by drop, followed by careful mixing to raise the pH (colour 
changed from yellow to orange/pink), which will formed the gel. The gel was incubated for 
20 min at 37 °C. RAFTTM absorber plungers (Lonza) were dropped carefully on top of the 
collagen gels to absorb liquid. The RAFTTM absorber plunger was removed after 20 mins, 
the astrocyte medium was added to the compressed gels, and the culture was incubated for 
24hr. hCMEC/D3 cells were seeded on top of the gel and grown over 2 days in modified 
EBM-2 medium (Table 2.1) until they formed a monolayer.  
Then, nanoparticles were added to the 3-dimensional co-culture gels at a final 
concentration of 8 μg/ml in modified EBM-2 media and incubated for 3 hrs at 37 °C. After 
the incubation, the medium was removed, the cultures were washed 3x in 0.5ml HBSS and 
fixed in 2.5% glutaraldehyde for 1 hr.  
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The compressed gels were washed x3 in PBS and gently detached from the bottom of the 
24 well plates with a spatula. They were then stored in phosphate buffer at 4 °C and 
processed for electron microscopy as described in Section 2.3.1.  
 
 
Figure 2.5 3-Dimensional co-cultures for nanoparticle uptake and transport assay. 
 
 
2.2.4 Alamar Blue assay to assess cell viability 
To assess toxicity of DNA-coated gold nanoparticles, Alamar Blue assay was performed. 
hCMEC/D3 cells were seeded in collagen-coated 96-well plates at 3x104 cells/per well and 
incubated in 5% CO2 in air at 37°C until they formed a monolayer (24 hours). Nanoparticle 
solution (100 µL/well) was then added at final concentrations between 8-50 µg/mL, testing 
nanoparticle formulations of NP-Gal, NP-DNA-40LO or NP-DNA-40HI. The cells were 
incubated with the nanoparticles for 24 hours. For positive control of toxicity 30 µg/ml 
digitonin was used by applying it for 30 mins on cells. As a negative control, no 
nanoparticles were applied on cells. 
After the incubation, the cells were washed with HBSS 3X and treated with 10% (v/v) 
Alamar Blue diluted in EMB-2 medium for 5 hours. Absorbance was then measured at 570 
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nm (to measure reduced form of Alamar Blue) and 620 nm (to measure oxidised form of 
Alamar Blue) using FLUOstar OPTIMA micro plate reader (BMG LABTECH, Ortenberg, 
Germany). The cell viability was calculated by the ratio of E570 (reduced form) /E620 
(oxidised form).  
 
 
2.2.5 Immunofluorescent microscopy of human astrocytes 
with GFAP marker 
Table 2.3 List of antibodies used in this study. 







1/2000 #AB5804, Millipore 
(U.K.) Ltd. 
Secondary  
Anti rabbit IgG 
antibodies AlexaFluor ® 




Rabbit IgG 10µg/ml #A11008 
Invitrogen Ltd. 
 
Human astrocytes were grown on collagen-coated coverslips. Once they were about 90% 
confluent, they were rinsed with HBSS and fixed with 4% (w/v) paraformaldehyde (PFA) 
in PBS for 20 min at room temperature. Cells were washed 3x in PBS. Coverslips were 
permeabilized and blocked in a solution of saponin (0.05% w/v) and normal goat serum 
(5% v/v) in PBS for 30 min. Then, cells were incubated with a primary antibody (1/2000 in 
PBS containing 2.5% goat serum and 0.05% saponin) for 1hr at room temperature. Then, 
coverslips were washed 3X in PBS containing 0.05% saponin on a shaker for 5 min and 
incubated with secondary antibody (10µg/ml in PBS containing 2.5% goat serum and 
0.05% saponin) for 1 hr at room temperature. After final 3X washes with PBS containing 
0.05% saponin on a shaker for 5 min, the coverslips were mounted with Dapi-Fluoromount 
medium (VECTASHIELD) and stored in the dark at 4 °C until they were imaged. Images 
were captured with an Olympus BX61 microscope using CellP imaging software. As a 
negative control, cells were incubated with diluent without primary antibody.  
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2.3 Localisation and quantification of nanoparticles in cells by 
Transmission Electron Microscopy 
 
2.3.1 Processing of samples for transmission electron 
microscopy 
During processing for transmission electron microscopy, all incubations mentioned in this 
section were performed at room temperature, and all solutions mentioned in this sections 
were applied to both insert and the bottom chamber. 
The cells were permeabilized in 0.01% Triton X100 for 15 minutes on a rocker and then 
washed 3x in 0.1 M PB). Silver enhancement (Aurion) was prepared according to the 
manufacturer’s instructions. Its function was pre-tested using a dot blot test – a drop of 
goat-anti-mouse IgG-gold (ultrasmall) (Aurion) was placed onto a membrane Amersham 
Hybond N+ (GE Healthcare) and incubated in silver enhancement solution for 30 min to 
show dark staining.  
Silver enhancement solution was applied to the inserts for 1 hr and 10 mins on a rocker and 
then washed 3x in distilled water. Cells were then osmicated in 1% (w/v) osmium tetroxide 
(in 0.1 M PB) for 30 min and then washed 3x in 0.1 M PB. The insert was removed from 
the well and its membrane was cut out. Then, the membrane was cut in half, where the 
middle part of one half was cut into a strip (~3 mm wide), which was then cut in half and 
edges were removed to create 2 squared pieces. The part towards the edge of each piece 
was noted by cutting the corner off. Finally, dehydration on the membranes was 
performed. Both insert membrane pieces were directly immersed in increasing 
concentrations of alcohol. The timings and concentrations of ethanol were as follows:  
30% ethanol for 5 min,  
50% ethanol for 5 min,  
70% ethanol for 10 min,  
100% ethanol for 10 min (performed twice),  
100% ethanol with molecular sieve for 10 min.  
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After dehydration, the membrane pieces were incubated in a 50:50 mixture of 100% 
ethanol and Epon resin (Agar) and placed on a rocker overnight. The next day the insert 
membrane pieces were penetrated with freshly prepared Epon resin and changed twice, 
each change was incubated for 2 hrs. The insert membrane pieces were embedded in Epon 
resin a cushion pad for 48 hrs at 60 °C. 
Samples embedded in resin blocks were prepared for microsectioning by removing the 
excess tip of the block to reach the sample. The block was then microsectioned to 80 nm 
thick sections (silver to gold coloured layers) using a diamond knife (Diatome, 
Switzerland). The 80 nm cut sections were collected onto pioloform film-covered copper 
grids.  After at least 2 hrs of air drying, they were counterstained with 3% aqueous uranyl 
acetate for 30 mins followed by Reynolds lead citrate for 10 mins.  
 
 
2.3.2 TEM quantification of nanoparticle uptake 
The sections were observed at a magnification of 20,000 x on JEM 1010 (Jeol).  The 
nanoparticles were counted in cells and sorted into 3 – 4 cell compartment categories; 
vesicles, cytosol, basal plasma membrane (under cell) and nucleus (illustrated in figure 
2.5) at the time of viewing on the electron microscope.  The nanoparticles are easily 
distinguished on electron microscope as they are very sharp black dots and decreasing 
contrast and brightness of electron microscope does not change their appearance, whereas 
other cell components fade/disappear. The length of the insert which was assessed on TEM 
(ranged usually between 300 – 1500 microns in length) was then imaged at low 
magnification (200x for JEM 1010) to get the length of the section assessed, using Image J 








2.4 DNA-coated gold nanoparticles in vivo  
All animal-related experiments of injection, perfusion, fixation, and organ removal were 
performed in Istanbul in collaboration with Mehmet Kaya and his colleagues. There were 5 
groups of rats, Wistar albino’s,  males, aged approx. 3 months. Each group consisted of 3 
rats that were injected with 200µg of gold nanoparticles/kg bodyweight as indicated in 
Table xx. 100 µL sterile isotonic saline was added to the dose of nanoparticles. The final 
volume of injected amount per animal was about 120 µl.   
 
Table 2.4 Number of animals per treatment group. 
 Intracarotid injection Intravenous injection 
NP-Gal 3 3 
NP-DNA-40LO 3 - 
NP-DNA-40HI 3 3 
 
Nanoparticles were infused into the left external carotid artery (intracarotid injections) or 
penile vein (intravenous injections) for over 1 minute. The nanoparticle solution was 
allowed to circulate for 10 minutes, after which the animals were perfused with cold 
isotonic saline for 20 mins. Before perfusion with isotonic saline, 2 ml of blood was 
removed and kept on heparin.  
After perfusion, brain, kidney, liver, lung, spleen, and heart were collected. Each one of the 
paired organs was immersed in fixative of 2% (w/v) PFA and 2.5% (w/v) glutaraldehyde 
(made in 0.1 M phosphate buffer) for TEM analysis, and the other was rapidly snap frozen 
for ICP-MS and qPCR analysis.  Heart was cut in half (vertically) and the two halves 
treated as above.  Brain was also cut in half (coronal) at bregma +1 and the posterior half 
was fixed whilst the anterior half was frozen.  [Note was made of which side was injected 
for intracarotid injections]. The fixed collected tissues for TEM analysis were kept in 
fixative (as above) for 2 hours at +4oC, and then the tissues were stored in PBS at +4oC.  
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2.4.1 Light and electron microscopy of fixed animal tissue 
samples  
Tissue samples were sectioned to 100µm thick vibratome sections (Leica). The sections 
were stored in 0.1M PB at 4°C for up to a week, then stored in a storage solution (high 
sucrose and ethylene glycol) at -20 °C. 
 
2.4.1.1 Light Microscope (LM) - silver staining for tissue samples 
100 µm tissue sections were stained using Aurion LM Silver enhancer (prepared using 
manufacturer’s instructions). The tissue samples were incubated for 40 mins with silver 
enhancement and imaged using a camera or a light microscope (Nikon, 1x). 
 
2.4.1.2 Transmission Electron Microscope processing 
A similar tissue section to the one stained with LM silver enhancer was selected. Selected 
tissue sections for all groups for all organs were placed in glass vials and permealized with 
0.05% Triton X100 for 30 mins and washed 3X with 0.1M PB. About 5-6 drops Aurion 
EM silver enhancer (prepared according to manufacturer’s instructions) were applied to 
each sample, and incubated for 2 hours at room temperature. Tissues were washed 3x with 
distilled water, and 1% (w/v) osmium tetroxide (in 0.1 M PB) was applied for 45 min. The 
sections were rewashed 3x with 0.1M PB, and subjected to the following dehydration in 
acetone procedure;  
o 30% acetone - 10 mins 
o 50% acetone - 10 mins 
o 90% acetone - 10 mins 
o 100% acetone x2 – 20 mins 
o 100% sieve (pure) acetone – 20 mins 
 
After dehydration, the tissue sections were incubated in a 50:50 mixture of 100% acetone 
and Epon resin and placed on a rocker overnight. The next day the tissue sections were 
penetrated with fresh resin with 2 changes, each incubated for 2 hrs. After that, tissue 
sections were flat embedded in Aclar sheets and incubated for 48 hrs at 60°C. Meanwhile, 
capsule-shaped resin blocks were prepared using gelatin capsules that were filled with 
Epon resin and polymerised for 48 hrs at 60 °C.  
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Once polymerised, a small piece (about 2 mm x 2 mm) was cut out of the flat-embedded 
tissue sections and glued (Super Glue) onto the resin capsules. Each block was 
microsectioned as described in 2.3.1.  
 
 
2.4.2 ICP-MS Analysis of gold present in animal tissues 
Quantification of the amount of gold by ICP-MS in the brain, kidney, liver, lung, spleen, 
heart, and blood was performed with help of Ibon Perera at Midatech in Bilbao, Spain. Due 
to their strictly confident methodology, they were not allowed to share more details with 
me apart of the digestion procedure of the tissues: 25% tetramethylammonium hydroxide 
(TMAH) + 0.2% x100 Triton and 1% HCL + 2 ng/ml iridium (Ir).  
The obtained values from the ICP-MS were levels of gold (ng) per g of tissue.   
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2.5 Quantification of DNA in solution and cells by qPCR  
SYBR Green 2X master mix kit was ordered from Qiagen. Forward and reverse primers 
were prepared with a stock concentration of 10 µM in order to have 0.5 µM concentration 
in a final 20 µl sample/reaction volume. Samples containing DNA template were diluted to 
working concentration.  At all times, reaction component preparation was performed on 
ice. Table 2.5 summarises the concentration and volume of reagents used per single 
reaction. 
Table 2.5 Components needed to run single qPCR reaction. 
Reaction Target Final 
Concentration 
Volume per single 20 
µl reaction 
2x SYBER Green Mix 1X 10 µl 
Forward Primer (10 µM stock) 0.5 µM 1 µl 
Reverse primer (10 µM stock) 0.5 µM 1 µl 
PCR grade water Make up to 20 µl 7 µl 
DNA template  1-10  pg 1 µl 
For qPCR quantification purposes, 4 treatment groups were selected; 40nt dsDNA alone, 
NP-Gal, NP-DNA-40LO, NP-DNA-40HI. 8µg/mL of nanoparticles for each group was 
applied for 3 hours incubation time in a 2D cellular transport assay. Media was collected 
from top chamber (apical side) and bottom chamber (basal side) of the trans-well, and from 
the hCMEC/D3 cell layer. Media collected from top and bottom of trans-well was 
immediately frozen and cells were lysed with 1% triton and frozen immediately at -20 ⁰C. 
The lysed cells, top and base media samples were used for DNA quantification. A positive 
control (40nt DNA template) was always included to make sure all the kit components are 
working correctly. A non-DNA template as negative control was included to determine if 
contamination was present. During qPCR, it was very crucial to avoid DNA cross-
contamination. Therefore, a designated clean laboratory set-up area was used as well as 
designated equipment. Extra care was taken to avoid pipetting errors during qPCR set up 
as the accuracy of qPCR is highly dependent on accurate pipetting and thorough mixing of 
solutions. Amplification and detection conditions were performed according to SYBR 
Green manufacturer’s guide; 2 min at 50°C, followed by 10 min at 95°C, followed by 40 
cycles of 15 s at 95°C, and 1 min at 55°C. The Ct values given out from qPCR for each 
sample were normalised using a standard curve (discussed in detail in chapter 6).  
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3 PREPARATION, CHARACTERISATION AND UPTAKE OF GOLD 
NANOCARRIERS WITH DNA 
 
Aim:  
The aim for work in this chapter was to prepare oligonucleotides attached to galactose-
coated gold nanoparticles NP-Gal and investigate their potential as a therapeutic delivery 
system into the brain. 
1. To prepare and characterize DNA coated NP-Gal. 
2. To understand what size oligonucleotide cargo can bind onto the NP-Gal and whether 
it can be transported across the brain endothelium in vitro 
3. To compare the cellular uptake and transport of different cargo sizes of DNA-coated 
nanoparticles crossing the brain endothelium in vitro, such as; 
- NP-DNA-20ss compared with NP-DNA-40ds 




As discussed earlier, drug delivery to the brain has many challenges due to the intrinsic 
properties of the BBB. The interface between blood plasma and brain consists of brain 
endothelium cells with tight junctions and the surrounding glia. BBB significantly restricts 
the passage of water-soluble, charged, and high-molecular weight therapeutics to the brain 
while allowing penetration of small and/or lipophilic molecules into the brain (BMC 
Neurology, 2009). In order to progress with effective treatment for neurodegenerative 
diseases such as Huntington Disease, brain cancer and stroke, which are extremely 
prevalent diseases, novel strategies must be developed to enhance the passage of 
therapeutic agents across the BBB.  
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One approach is to use nanoparticle carriers, especially gold nanoparticles. Gold 
nanoparticles may be a useful agent in treating brain disorders. Gold nanoparticles have 
many advantages such as simple synthesis, chemical stability, narrow-size distribution, 
easy surface functionalisation, and low toxicity providing promising methods to solve 
many challenges in contemporary medicine (Freese et al. 2013).  Previous experimental 
data obtained by Gromnicova et al, 2016 in our research group showed that gold 
glyconanoparticles <5 nm can enter rat brain. Therefore, they may have potential as a 
delivery system of therapeutic molecules into the brain. Therefore, my research has mainly 
focused on delivering therapeutic oligonucleotides into the CNS without disrupting the 
BBB. The novel approach consists of using <5nm gold galactose coated nanoparticles (NP-
Gal) as a nanocarrier to deliver oligonucleotides (thiol DNA) into the brain. For this 
project, covalently attached oligonucleotide-gold nanoparticles were prepared using 20nt 
and 40nt thiol-DNA and ~2nm gold core NP-Gal. DNA was used instead of RNA due to 
its higher stability. 
 
 
3.2 Results  
Place exchange reaction was used to attach thiol-DNA to gold nanoparticles. In this 
reaction, excess amount of thiolated DNA attaches covalently to the stable nanoparticle 
coated with thiolated galactose ligands, whilst releasing galactose ligands in exchange.  
 
 
3.2.1 Selection of gold nanoparticles 
Nanoparticles used throughout the project were ~2nm gold core and had covalently 
attached galactose ligands. Galactose ligand was attached to gold nanoparticles because the 
previous study by our research group (Gromnicova et al, 2014) showed that galactose 





3.2.2 Selection of DNA sequence 
20nt Thiol-C6-DNA selection - For the sequence of DNA with 5’ C6 spacer and thiol 
group (referred to as thiol-DNA), we selected a 20nt DNA sequence - AAT ATC GCG 
GAC AGA AGA CG. The selected DNA sequence was derived from a GFP gene (green 
fluorescence protein), obtained from a plasmid of a bacteria Neisseria gonorrhoeae 
(pCmGFP) (GenBank: FJ172221.1). The selected sequence is not present in the genome of 
mammalian cell or human cell.  
Homology of the sequence was assessed by BLAST search (NCBI) to any gene in the 
mammalian and human genome, as we used human brain endothelial cells and astrocytes 
for in vitro studies and in vivo experiments on rats. The maximal homology with the 
human genome was 29/40 nucleotides with three gaps. There was no detectable homology 
with the rat genome. 
  
40nt DNA selection – For the sequence of 40nt DNA, we selected a sequence of 5’ – 
AAAAGCTCTGCCTTGGTTTCCGTCTTCTGTCCGCGATATT-3’ by BLAST search 
(NCBI). The 40nt sequences had the first 20nt base pairs complementary to the thiol-DNA 
(above). During the selection, we made sure that the selected sequence is not present in the 
genome of a rat or human genome. 
 
 
3.2.3 Detection of DNA attached to the galactose gold 
nanoparticles by electrophoretic mobility shift assay 
(EMSA) 
EMSA (electrophoretic mobility shift assay) was used to detect nanoparticles with 
different numbers of DNA molecules attached to each nanoparticle. EMSA is generally 
used to detect proteins (i.e. transcription factors) binding onto a specific sequence of DNA. 
The binding of a protein to DNA affects the mobility of DNA in the gel as it migrates at a 
slower rate than the free linear DNA fragments once the current is applied. In our case, we 
were detecting DNA molecules bound onto gold nanoparticles. The more DNA molecules 
the gold nanoparticles had attached to it, the nanoparticles would move slower through a 
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polyacrylamide gel and thus producing a DNA-NP band that is towards the top of the gel 
(figure 3.1- right).  
Additionally, using EMSA for the separation of nanoparticles with different numbers of 
DNA molecules attached to the gold nanoparticle is a novel use of this technique. Other 
techniques have been used to separate DNA-coated gold nanoparticles from uncoated ones. 
For example, fluorescent-based methods or agarose gel electrophoresis can isolate the 
nanoparticles from the gel. (Pellegrino et al. 2007) (Sandstrom et al. 2003; Pellegrino et al. 
2007; Zanchet et al. 2001).  
 
         
 
Figure 3.1 Gold nanoparticle attached with double stranded DNA thiol-ssDNA hybridized with 
complementary 20nt-bp of biotinylated DNA for EMSA detection (left), summarising what each 
band on the acrylamide gel for EMSA detection represents (right). 
 
 
3.2.4 Optimising place exchange reaction to maximise DNA 
molecule attachment to the nanoparticle 
Initial experiments were carried out to optimise the best time of incubation at which the 
place-exchange reaction took place. This was important as we needed to attach the 
maximum number of thiol DNAs to each nanoparticle. The experiment was set to test 
incubation time for reaction over a different number of days (day 1, 2, 3, 4, and 7), with 
molar excess ratio of thiol-DNA of 14: 1 DNA: NP at 37° C (the DNA used was in non-
reduced form as supplied). 
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Figure 3.2 of EMSA gel of the place exchange reaction set over a different number of days 
shows no bands higher up in the gel. This could suggest that the DNA was not attaching to 
the nanoparticles, and hence, no bands were observed. The reason for no DNA molecules 
attaching to the nanoparticles might have been that the thiol-DNA was in oxidised form. 
Oxidised form of DNA (dimer) is not able to attach onto the nanoparticles due to having its 
thiol group occupied. 
 
Figure 3.2 Initial experiment of place exchange reaction with 14nmol DNA : 1nmol NP ratio set 
over different number of days (day 7, 4, 3, 2 &1) shows no bands of DNA-attached to gold 
nanoparticles. The control (DNA probe); 20nt-Biotinlayted DNA. The experiment was performed 
on 6% acrylamide gel and blotted on nylon membrane and detected by a chemiluminescence 
detection kit. 
 
3.2.4.1 DNA reduction 
Since oxidised (dimer) disulphide DNA does not have free thiol group to attach onto the 
nanoparticles, the next step comprised reducing dimerized DNA to free up thiol groups to 
attach onto the nanoparticles. Reducing reagents dithiothreitol (DTT) and tris(2-
carboxyethyl)phosphine (TCEP) were tested (Figure 3.3 –A). The addition of DTT to DNA 
(molar ratio of 2nmol DTT: 1nmol DNA) left most DNA dimers in oxidised form, 
similarly to control treatment with water only. On the other hand, TCEP reduced most of 
the DNA dimers.  
Therefore, TCEP was selected as a reducing agent. Then, we tested different number of 
molar ratio concentrations of TCEP versus DNA (1.25nmol TECP: 1nmol DNA & 2nmol 
TCEP: 1nmol DNA) with a different number of the incubation time (1 hr, 2hrs, & 4 hrs).  
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Figure 3.3- B shows that the most suitable conditions to reduce thiol-DNA were molar 
ratio of 1.25nmol TCEP: 1nmol DNA) and incubated for 4hours (as all DNA was in 
reduced form by 4 hours). The ratio of 1.25nmol: 1nmol compared to 2nmol: 1nmol was 
selected to keep minimal concentration of the reducing agent. In that way, there was very 
little free reducing reagent left in the nanoparticle-DNA mixture. The reason for this is that 
excess reducing reagent can detach thiol-DNA from the nanoparticles after the place 
exchange reaction has taken place. 
 
 
Figure 3.3 Different reaction conditions to reduce dimer-DNA. Image A represents DTT reducing 
reagent. Image B represents TCEP reducing reagent. The experiment was performed on 15% 
acrylamide gel and blotted on nylon membrane and detected with a chemiluminescence. 
 
3.2.4.2  Optimisation of incubation time for the place exchange 
reaction  
Following reduction to unprotect the thiol-DNA, a place exchange reaction to bind thiol-
DNA onto gold nanoparticles was performed. The incubation time for the place exchange 
reaction to take place was set over a different number of days; day 1, day 2, day 3, and 4. 
The ratio was kept at 14nmol-DNA (DNA in excess) to 1nmol gold nanoparticles (14:1). 
Mixed gold nanoparticles and reduced thiol-DNA was immediately flushed with nitrogen 
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gas (to avoid oxidation of free DNA molecules) in a sealed box and kept at 37 °C for day 
1, 2, 3 and 4.  
The results in figure 3.4 show the incubation time that was needed for the place exchange 
reaction to form DNA-attached gold nanoparticles. The probe is biotin attached 20nt DNA, 
which represents a band of monomeric DNA only. At day two, strong gel bands and the 
highest number of bands were observed at the top of the gel, compared to other days. After 
two days, the dimer (oxidised DNA) band starts to get darker/stronger. At this point, the 
gold nanoparticle may have reached the maximum number of DNAs they could attach, and 
the free DNA in the mixture has started to dimerize.  
When the band density was measured (Figure 3.5), day 2 showed higher DNA loading on  
nanoparticles (band 5 and 6) compare to the rest of the days (results summarised in graph-1 
below). Therefore, for all future experiments, an incubation time of 2 days was selected for 




Figure 3.4 Electrophoretic mobility shift assay of DNA attached gold nanoparticles using a 
biotinylated DNA probe. Probe only = biotinylated complementary sequence of thiol-DNA. The 
bands identified as nanoparticles with DNA and free DNA, in a monomeric form (Thiol-DNA), or 
dimerized. The probe of biotin DNA alone is used as a control, which shows the bands for 





Figure 3.5 Analysis of band density from the EMSA blot of the 4 days-place exchange reaction. 
The band density was analysed with ImageJ by measuring the darkness of the each band on the 
EMSA blot.  
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3.2.5 Cellular uptake comparison of DNA attached gold 
nanoparticles 
Aim- Compare the transport rate across brain endothelium of nanoparticles with 
different numbers of DNA molecules (2D in vitro experiments). 
 
In a previous study, Gromnicova et al, 2014 pointed out the possibility that higher DNA 
density coated nanoparticles may increase the uptake efficiency of gold glyco-
nanoparticles. Therefore, we compared the uptake rate of nanoparticles with different 
amounts of DNA attached into cells. 
                                                                                                                                                               
In vitro BBB model in the form of human brain endothelial cell line hCMEC/D3 was used 
to test the uptake rate of DNA-attached gold nanoparticles.  Since brain endothelial are the 
first line of cells that are in contact with the blood plasma in vivo, and therefore would 
interact with DNA-attached gold nanoparticles.  
 
3.2.5.1  Cellular Uptake of pre-fractionated 20nt ssDNA attached 
nanoparticles compared to pre-fractionated 20nt dsDNA 
attached nanoparticles 
 
To test the uptake rate of different quantities of DNA attached gold nanoparticles, three 
dose groups (illustrated in figure 3.6) were prepared, i.e. control NP-gal, ssDNA-coated 
nanoparticles and dsDNA coated nanoparticles.  
They contained an excess free DNA and unbound gold nanoparticle in the mixture. 
Therefore we called this a pre-fractionated preparation. (*Fractionation terminology and 






Control – NP-Gal (no DNA attached)  
                                                                                                                               
ssDNA attached nanoparticles (NP-DNA-20ss) 
                                           
dsDNA attached nanoparticles (NP-DNA-20ds) 
A complementary DNA was hybridized with the NP-DNA-20ss in order to form NP-DNA-
20ds. 
  
Figure 3.6 Illustrative images for NP-Gal, NP-DNA-20ss and NP-DNA-20ds; the images are 
diagrammatic (heterogeneous with respect to how many DNA molecules were attached and not to 
scale). 
 
The results of comparing the uptake of NP-DNA-20ss with NP-DNA-20ds into brain 
endothelial cells are shown in figure 3.7 and figure 3.8. Nanoparticles were quantified in 
the cell cytosol, vesicles, in the nucleus and under-cell (illustrated in figure 2.6 in 
chapter 2). As the NP-Gal used had ~2 nm gold core, they were not visible within cells by 
the electron microscopy unless silver-enhanced. Silver enhancing the gold nanoparticles 
increased the size of these ~2 nm nanoparticles to about 20 nm. Therefore, for all 
nanoparticle transport assay studies, electron microscopy along with silver enhancing the 
~2nm gold nanoparticle was used in order to track the nanoparticles intracellularly. 
NP-DNA-20ds had a significantly greater number of nanoparticles in vesicles compared to 
both the control NPs and the NP-DNA-20ss. The NP-DNA-20ss showed increased uptake in 
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vesicles compared to the control alone. Notably, there is an unusual increase in cell uptake 
in the nucleus, which may be due to damage to the nuclear membrane.  
 
 
Figure 3.7 Uptake comparison of NP-DNA-20ss with NP-DNA-20ds into brain endothelial cells. 
Nanoparticles quantified in cell cytosol, vesicles and in nucleus. The control= NP-Gal. Three 
experiments were performed, each individual experiment having three technical repeats. Tukey's 
multiple comparisons test was performed using GraphPad. There is significant difference for NP-
DNA-20ds compared to NP-Gal in vesicles (p-value: 0.0034) and NP-DNA-20ds compared to NP-






Figure 3.8 Electron micrographs of silver enhanced gold nanoparticles with attached DNA in 
hCMEC/D3 cells. More number of NP-DNA-20ds (dsDNA) nanoparticles were observed in vesicles 





3.2.5.2 Pre-fractionated NP-DNA-20ds compared to pre-fractionated 
NP-DNA-40ds 
Since we observed higher cellular uptake of NP-DNA-20ds compared to NP-DNA-20ss in 
the brain endothelial cells, we decided to prepare nanoparticles with longer (40nt) DNA 
attached. Longer DNA molecule would allow us to quantify DNA in the cells/tissue with 
PCR and RT-qPCR. Moreover, we wanted to determine if a larger oligonucleotide cargo 
can be transported into and across brain endothelial cells.  
To keep costs at minimum, we decided to keep the 20nt thiol-DNA and hybridise it with a 
40nt ssDNA which had 20 base pairs complementary to the thiol-DNA. Another 20nt 
ssDNA was added to compliment the last 20 nucleotides on the end of the 40nt ssDNA to 
make a NP-DNA-40ds (refer to chapter 2.1.2.1). 
 
3.2.5.2.1 Detection of 40nt dsDNA nanoparticles  
EMSA was performed to analyse the attachment of 40nt DNA onto the gold nanoparticles. 
As shown in figure 3.9, there is a shift up of the bands for 40 nucleotides compare to the 20 
nucleotides. This confirms hybridization of 40nt DNA onto the nanoparticles. Band B is 
relatively strong and it likely indicates presence of free monomer of 40nt ssDNA and 





Figure 3.9 A representative electrophoretic mobility shift assay of NP-DNA-20ds and NP-DNA-
40ds. The probe (biotin DNA) is used as a control, which shows the bands for monomeric DNA 
only. There are duplicate bands for each NP-DNA-20ds and NP-DNA-40ds. The bands higher up 
the gel (A) represent the nanoparticles attached with DNA, the band (B) shows dimerized DNA, 
and right at the bottom (C) is the free DNA in a monomeric form (Thiol-DNA). Three EMSA 
experiments were carried out to confirm the results. 
 
3.2.5.2.2 Cellular Uptake of pre-fractionated NP-DNA-20ds 
compared to pre-fractionated NP-DNA-40ds 
 
NP-DNA-40ds were investigated in their uptake efficiency in brain endothelial cells.  
Three dose groups (illustrated in figure 3.10) were prepared to compare the transport rate 
of NP-DNA-20ds compared with NP-DNA-40ds on D3 cells. These groups contained 









1) Control – NP-Gal 
                                                                               
2) NP-DNA-20ds 
                                             
3) NP-DNA-40ds 
 
Figure 3.10 Illustrative images for NP-Gal, NP-DNA-20ds and NP-DNA-40ds; the images are 
diagrammatic (heterogeneous with respect to how many DNA molecules were attached and not to 
scale). 
  
The cellular uptake of NP-DNA-20ds compared withNP-DNA-40ds into brain endothelial 
cells is shown in Figure 3.11 and Figure 3.12 Nanoparticles were quantified in the cytosol, 
vesicles, nucleus, and at the basal membrane (under-cell). As a control, we used NP-Gal 
with no DNA attached. There was a statistically significant increase in cell uptake of NP-
DNA-40ds compared to both NP-Gal and NP-DNA-20ds. The NP-DNA-40ds nanoparticles 
showed almost three times more cell uptake in cellular vesicles. Since the amounts of 
nanoparticles observed at the basal membrane (under-cell) was higher, it is possible that 
the nanoparticles were more likely crossing through the cells in comparison with the NP-























































Figure 3.11 Comparison of uptake of NP-DNA-20ds and NP-DNA-40ds into brain endothelial 
cells. Nanoparticles were quantified in the cell cytosol, vesicles, nucleus, and at the basal 
membrane (under-cell).  NP-Gal was the nanoparticle control, no DNA attached. Three 
experiments were performed, each experiment having three technical repeats. Tukey's multiple 
comparisons test showed significant difference for NP-DNA-40ds compared to NP-DNA-20ds in 






Figure 3.12 Electron micrographs of DNA-attached gold nanoparticles of various nucleotide 
lengths on hCMEC/D3 cell line. Many nanoparticles were observed in vesicles and crossing 
through the cell for the NP-DNA-40ds (40nt) compared to NP-DNA-20ds (20nt) and NP-Gal 





For effective brain drug delivery, we used galactose coated gold nanoparticles with a 2nm 
gold core as nanocarriers of DNA into brain endothelial cells. DNA coated gold 
nanoparticles were synthesized by place exchange reaction, a simple method to attach 
DNA onto gold nanoparticles. The thiol DNA attaches covalently to the nanoparticle 
coated with thiol galactose ligands, releasing the galactose ligand in exchange. We found 
that molar ratio of 14:1 (DNA: NP) with an incubation time of 48 hours, flushed with 
nitrogen gas, and incubated at 37 °C were the optimal conditions to coat nanoparticles with 
maximum number of DNA molecules.   
To assess the effectiveness of the reaction, EMSA gel filtration was used. It effectively 
separated nanoparticles with different densities of DNA molecules. Six different bands 
were observed on EMSA, which possibly demonstrated that up to 6 DNA molecules 
attached per nanoparticle. However, it is not proven that the equally-spaced EMSA bands 
correspond to 1, 2, 3, 4, 5 and 6 DNA molecules attached to each nanoparticle. As EMSA 
is a novel technique for detection of DNA attached to gold nanoparticles, no NP-DNA 
standards were available to compare our samples. 
After preparing DNA attached gold nanoparticles with 20nt or 40nt long DNAs were 
assessed for their cellular uptake efficiency across human brain endothelial cells 
(hCMEC/d3). We examined the difference in uptake ofNP-DNA-20ss compared to NP-
DNA-40ds and of the NP-DNA-20ds to NP-DNA-40ds.Nanoparticle cell uptake assays for 
NP-DNA-20ds showed significantly higher vesicular transport compared to NP-DNA-20ss. 
In comparison to the control uncoated nanoparticles, NP-Gal, NP-DNA-20ss had 
significantly higher vesicular transport.  
When comparing double-stranded version on DNA-coated nanoparticles, the more 
negatively-charged nanoparticles (40nt) had significantly higher uptake efficiency in both 
cytosolic and vesicular localisations. Furthermore, more nanoparticles were observed at the 
basal membrane for NP-DNA-40ds. This may mean that a higher number of nanoparticles 
was crossing the cell from the apical side (blood) compared with NP-DNA-20ds and the 
uncoated NP-Gal. Additionaly, from the electron micrographs of NPs uptake experiments, 
one may question that the NPs may just remain attach to the collagen coated trans-well and 
not pass through to the basal side into the medium. Due to set up of our experiment it was 
not possible to test the basal side media on TEM, as only fixed cells were possible to 
image. Therefore, in chapter 6; experiments were performed for detection of DNA on the 
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other side of the trans-well membrane (in basal media) using quantitative PCR. The 
movement of free 40nt dsDNA and 40nt dsDNA attached NPs was tested across the trans-
well system. Chapter 6 experiment of DNA movement is a good evidence of transcellular 
migration as it shows that the gold nanoparticles seen on the basal side of cells did not 
remained attached to the collagen-coated trans-well membrane (as seen on the electron 
micrographs) but to passed through into the basal side media.  
Overall, we found that pre-fractionated (crude) mixture of larger (in size due to more 
nucleotides) and negatively-charged DNA attached nanoparticles had increased cellular 
uptake in human brain endothelial cells when compared with uncoated nanoparticles.  
A possible way our DNA attached nanoparticles may have crossed brain endothelial cells 
is via adsorptive-mediated transcytosis. The adsorptive-mediated transcytosis involves 
binding of the proteins (by electrostatic interaction with the luminal surface of the 
endothelium) to the endothelial cell surface to cross the endothelium. Charge is a key 
parameter of NPs known to influence their cellular uptake as well as cytotoxicity (Hühn et 
al, 2013). For example, Cho et al, 2017 reported that the uptake rate of cationic gold 
nanoparticles into the SK-BR-3 cell line was fivefold higher than their anionic 
counterparts. The authors also explained that half of the cationic gold nanoparticles diffuse 
into cells by non-endocytosis pathways. This may occur by creating holes or other 
disruptions in the plasma membrane. In contrast, anionic and neutral gold nanoparticles are 
internalized into cells only via endocytosis pathways. Additionally, an alternative cell 
uptake assay of charged gold nanoparticles coated with galactose/PEG-amine was 
completed in our group (Gromnicova et al., 2014). I confirmed in my own observations 
that positively charged gold nanoparticles coated with galactose/PEG-amine had higher 
cell uptake in both the cytosol and vesicles compared to only galactose nanoparticles. The 
uptake of positively charged nanoparticles may be promoted because the positive charge of 
nanoparticles may have interacted with endothelial cells negative surface charge (negative 
surface charge due to glycocalyx; a negatively charged layer that covers the luminal 
surface of endothelial cells). Behzadi et al, 2017 also pointed out that electrostatic 
interaction between charged nanoparticles and the cell membrane is of great importance. 
Their study showed the adhesion of positively charged nanoparticles to the cell membrane 
which may promote membrane-wrapping phenomena. A fully membrane-wrapped 
nanoparticle does not easily detach from the cell membrane and has more chances of 
entering the cell. Likewise the positively charged nanoparticle, perhaps our negatively 
charged nanoparticles may have been attracted towards positive proteins found on the 
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endothelial cells that may have helped to facilitate their uptake, though this area still needs 
thorough investigation; of how the negative charge interacts with endothelium cell surface 
proteins.  
Furthermore, from electron micrographs we observed that our gold nanoparticles coated 
with more DNA molecules appeared to have a tendency for active vesicular pathway rather 
than the passive cytosolic pathway. Size may also be key to determine the uptake pathway 
of the nanoparticles. Chithrani et al, 2006 investigated gold nanoparticle size and its effect 
on the transcellular pathway on many different cell lines. In their study, 40nm gold 
nanoparticles were taken up via active cellular pathway, whereas 2 nm gold nanoparticles 
used passive pathway to enter cells. For future studies it would be useful to test the 
“active” pathway by additional experiments of nanoparticles transport in cells using 
temperature dependant experiments such as 4 °C vs 37 °C.  
Nonetheless, there are various other factors apart from the size or charge, which may have 
affected the uptake efficiency of the DNA attached nanoparticles that we observed. Such 
factors may be that having more or longer DNA around nanoparticle increases the overall 
nanoparticle radius, causing the DNA to wrap around the nanoparticle completely. Smith et 
al, 2007 theoretically showed that a fully membrane-wrapped nanoparticle does not easily 
detach from the cell membrane and, therefore, has more chances of entering the cell.  To 
explain the difference in uptake of our single stranded versus double-stranded DNA 
attached to nanoparticles, it is possible that ssDNA rearranges itself around the gold core 
differently than dsDNA. As dsDNA or 40nt dsDNA has a negatively charged compared to 
the ssDNA and 20nt DNA, it might rearrange to be as far apart from other strands of DNA 
as possible due to the negative charge repulsion.  
Moreover, as our investigation included a mixture of nanoparticles with attached DNA 
along with free DNA and uncoated nanoparticles, it was not clear whether the gold 
nanoparticles we detected via electron microscopy were indeed DNA-coated. Therefore, 
from these observations, we decided to remove the unreacted free DNA and uncoated 
nanoparticles from the mixture.   
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4  FRACTIONATION OF REACTION MIXTURE OF NP-DNA-40 
AND ITS UPTAKE EFFICIENCY ON 3D CO-CULTURE MODEL OF 
THE BLOOD BRAIN BARRIER. 
 
Aims 
1. To isolate NP-DNA-40ds with different numbers of 40nt DNA molecules attached 
to each nanoparticle using FPLC.   
2. Next, to assess their uptake efficiency into brain endothelial cells and astrocytes, 




In the previous chapter, we compared the uptake efficiency of NP-DNA-20ss with NP-
DNA-20ds and NP-DNA-20ds with NP-DNA-40ds.  All the nanoparticle formulations were 
a mixture of free (unbound) DNA and gold nanoparticles along with nanoparticles coated 
with DNA. Therefore, to minimise other factors that could affect the uptake of 
nanoparticles on the cells, it was essential to remove the unreacted free DNA and 
nanoparticles from the mixture.  
For this purpose, we used FPLC (fast protein liquid chromatography) to remove unreacted 
nanoparticles and unreacted DNA. FPLC provides a high-resolution characterisation and 
separation of protein (and our DNA-coated nanoparticles) by small-diameter microbeads. 
Smaller size molecules elute last as they enter inside the microbeads and travel slower. 
Larger size molecules elute first as they travel faster because they do not enter the 
microbeads (Madadlou et al, 2011). This technique also allowed us to separate DNA-






4.2 Results  
 
4.2.1 FPLC (fast protein liquid chromatography) separation 
of nanoparticle mixture (fractionation) 
We decided to use NP-DNA-40 for all further in vitro and in vivo studies because of its 
higher cellular uptake into brain endothelial cells compared with NP-DNA-20ds. Moreover, 
using NP-DNA-40 allowed us to amplify 40nt DNA by qPCR and detect DNA in cells. 
Chapter 6 describes in detail the results of how much DNA can be transported across the 
endothelial cells in vitro. 
However, we came across difficulties when resolving the nanoparticle formulation of NP-
DNA-40ds. During separation, the column reached its limit of separating large molecules 
and it made it difficult to distinguish different sizes of molecules (peaks). Hence, we 
decided to separate NP-DNA-20ss formulation instead (as shown in Figure 4.1), which our 
FPLC column separated easily. We then pooled selected fractions together before 
extending the attached DNA molecule from 20nt to 40nt. 
Therefore, we prepared NP-DNA-40 of different DNA densities (low and high density) 
following these steps: 
1. Fractionate NP-DNA-20ss (Figure 4.1) 
2. Pool selected fractions to make nanoparticle formulations with high and low DNA 
density 
3. Extend attached DNA molecule to form NP-DNA-40ds by hybridisation 





Figure 4.1 FPLC trace of NP-Gal with 20nt Thiol DNA place exchange reaction. Numbers in red 
show the fraction number at which the different size molecules were eluted. The elution volume; 
0.5ml at flow rate of 0.4 ml/min.  All drawings on top of peaks (DNA molecules or NP-DNA 
molecules) are illustrative for explanation purposes only. 
 
In order to confirm whether the nanoparticle peaks (in figure 4.1) detected by FPLC 
corresponded to nanoparticles with an increasing number of 20nt DNA molecules attached 
on each nanoparticle, EMSA was performed (as described in chapter 3). Figure 4.2 shows 
free DNA in fraction 28 and 29 with no bands showing higher up the gel, confirming that it 
does not contain any nanoparticles. Similarly, no bands of NP-DNA were observed in 
fraction 25 and 26.  Dimerised DNA was observed in fraction 25 and 26.  Fraction 15, 16, 
17, 18, 19 and 20 showed bands at the top of the gel confirming that those fractions 
contained nanoparticles with DNA molecules attached. The more DNA molecules attached 
to each nanoparticle, the larger it would be and hence would move slower on the EMSA 
gel. We observed at least 6 separate bands on the gel, demonstrating that perhaps we had 
up to 6 different formulations of DNA coated nanoparticles.  
To create nanoparticle formulations with high and low DNA density, we decided to pool 
some of these fractions together. Fractions 19 and 20 lacked the upper bands, hence were 
pooled to make a formulation of nanoparticles with low density DNAs attached. Fractions 
15 and 16 lacked the lower 3 bands while fraction 17 lacked the lower 2 bands, hence were 
all pooled together to form formulation of nanoparticles with high density DNAs attached. 





Figure 4.2 EMSA on a 6% gel was performed to investigate whether the nanoparticle peaks 
eluted at different fractions detected by FPLC corresponded to nanoparticles with increasing 
number of DNA molecules attached. Numbers in red are fraction numbers corresponding to Figure 
4.1. One time large batch of NP-DNA-40LO and NP-DNA-40HI was prepared and used for 
cytotoxicity tests, in vitro uptake comparison on the brain endothelial cells and in vivo experiments. 
 
Next, we extended 20nt single-stranded DNA attached on the nanoparticles into a 40nt 
double-stranded DNA. The reaction mixture was fractionated again to remove unreacted 
40nt and 20nt DNA, as illustrated in figure 4.3a (low-density DNA nanoparticle 
formulation NP-DNA-40LO) and figure 4.3b (high-density DNA nanoparticle formulation 
NP-DNA-40HI). The hybridisation and extension of 40nt DNA was successful as the NP-
DNA-40 eluted out earlier at fraction 11 rather than fraction 15 (for 20nt DNA). Free 40nt 






Figure 4.3 (a) NP-DNA-40LO and (b) NP-DNA-40HI. FPLC fractionation performed to remove 
excess 40nt and 20nt DNA after hybridisation reaction to create 40nt long dsDNA attached onto 
the nanoparticles. NP-DNA-40LO has a broader peak than NP-DNA-40HI because of different 
volumes of NP-DNA-40ds used in fractionation column. We had more of NP-DNA-40HI as three 
fraction (Fraction: 15, 16 and 17 having 1.5 ml of total sample) were pooled compared to NP-
DNA-40LO (Fraction: 19 and 20 having 1ml of total sample). 
 
To conclude, we prepared two formulations of 40nt DNA attached nanoparticles;  
- NP-DNA-40LO – low-density DNA formulation with fewer 40nt DNA molecules 
attached on each nanoparticle (I.e. probably 1 or 2 strands of 40nt DNA to each 
nanoparticle)* 
- NP-DNA-40HI- high density DNA formulation with more 40nt DNA molecules 
attached on each nanoparticle (I.e. probably 4-5 strands of 40nt DNA to each 
nanoparticle)* 
[* We hypothesized that the equally-spaced EMSA bands corresponded to 1, 2, 3, 4 
and 5 DNA molecules attached to the NP. However, as this is a novel technique, no 
NP-DNA standards were available to compare with the samples prepared here.] 





4.2.2 Hydrodynamic diameter of DNA-nanoparticles 
Hydrodynamic diameter of proteins with known molecular weight was annotated by FPLC 
to generate standard curve from proteins elution volume (Figure 4.4).  To get the 
hydrodynamic diameter of the nanoparticles, elution volumes by FPLC of each of the 
nanoparticles were interpolated with the protein standard curve and molecular weights 
were read off. Once the molecular weights were known, they were converted to nm to get 
the hydrodynamic diameter value in a nm for a spherical molecule of that particular 
molecular weight. But to bear in mind our DNA coated nanoparticles are different from 
globular proteins. The hydrodynamic diameter of different density DNA coated 
nanoparticles are summarised in table 4.1. NP-DNA-40LO (+1x40nt +2x40nt) has a 
hydrodynamic diameter of 7.5nm and NP-DNA-40HI (+3x40nt + 4x40nt) has a 
hydrodynamic diameter of 7.6nm. NP-Gal as expected has hydrodynamic diameter of 
1.8nm while, 20nt DNA coated nanoparticles had hydrodynamic diameter ranging from 
3nm to 4nm depending on different numbers of DNA strands attached. 
 
Figure 4.4 Standard curve of globular proteins (with known molecular weight) annotated by 






Table 4.1 Hydrodynamic diameter of NP-Gal and DNA coated nanoparticles. +1x40nt – 
refers to nanoparticle with 1 strand DNA. 
Particle                          Hydrodynamic diameter  (nm)       
NP-Gal                            1.8 
+ 1x20nt                         3.1                                 +1x40nt        7.5 
+ 2x20nt                         3.6                                 +2x40nt        7.5 
+ 3x20nt                         3.8                                 +3x40nt        7.6 
+ 4x20nt                         4.0                                 +4x40nt        7.6 
 
 
4.2.3 Cytotoxicity of DNA-coated nanoparticles on brain 
endothelial cells 
To investigate cytotoxicity of the NP-Gal, NP-DNA-40LO and NP-DNA-40HI, Alamar blue 
assay was used.  Alamar Blue uses resazurin as an oxidation-reduction (REDOX) indicator 
where a colour change is formed in response to cellular metabolic reduction. The reduced 
form of Alamar blue is pink and highly fluorescent, meaning that more living/respiring 
cells will produce a bright pink colour change from the blue (O’Brien J et al, 2003). 
We tested the effect of different concentrations (8µg/ml, 16µg/ml, 32µg/ml and 50µg/ml) 
of the three nanoparticles formulations on viability of brain endothelial cells at 24hrs. We 
found no reduction of cell viability on exposure to concentrations of 8µg/ml, 16µg/ml and 
32µg/ml for NP-DNA-40LO, NP-DNA-40HI and NP-Gal for up to 24 hours (figure 4.5). At 
a concentration of 50µg/ml, NP-Gal and NP-DNA-40LO showed low cytotoxicity, whereas, 
NP-DNA-40HI showed no cytotoxicity at 50µg/ml. It is possible that cells exposed to 
higher concentration of the nanoparticles will take up and transport higher number of 
nanoparticles across the cell. This may cause large quantities of nanoparticles gathering at 
the bottom of the well underneath the cell, perhaps causing it to detach and die. 
Since all our experiments of nanoparticle uptake assays were performed using 
concentration of 8µg/ml, and for 3 hours, we can conclude that such dose was not 




Figure 4.5 hCMEC/D3 cell viability measured by Alamar blue assay when exposed to 8, 16, 32 
and 50 µg/mL of NP-DNA-40LO, NP-DNA-40HI and NP-Gal for 24 hours (n=3). Positive control of 
cell death is 30 µg/ml digitonin (30 min treatment). Notes: Data are shown as ratio of E570 
(reduced form) /E620 (oxidised form) which represents the maximum cell viability. Tukey's 
multiple comparisons test showed significant difference for NP-Gal and NP-DNA-40LO applied at 
50 µg/mL (p-value: * 0.026, **0.0084. 
 
 
4.2.4 Uptake comparison of fractionated NP-DNA-40LO and 
NP-DNA-40HI on the brain endothelial cells 
We assessed uptake efficiency of nanoparticle formulations of NP-DNA-40LO and NP-
DNA-40HI on brain endothelial cells in 2D cultures, as well as in 3D co-cultures with 
human primary astrocytes. As mentioned in chapter 2 the nanoparticles were used at 
concentrations of 8 μg/ml incubated for 3 hours at 37 °C for cell studies unless described 
otherwise. 
 
4.2.4.1  Uptake comparison on the 2D model of the blood-brain 
barrier  
We found that there were significantly higher numbers of NP-DNA-40LO nanoparticles in 





































NP-Gal. NP-DNA-40HI showed higher numbers of nanoparticles in vesicles compared to 
both the NP-DNA-40LO and NP-Gal.  
Overall, both formulations of NP-DNA-40LO and NP-DNA-40HI had higher uptake 
efficiency and appeared more likely at the basal membrane of the endothelium compared 

























































Figure 4.6 Uptake efficiency of NP-DNA-40LO and NP-DNA-40HI compared with NP-Gal in the 
brain endothelial cells grown on trans-well inserts (2D BBB model). Nanoparticles were applied at 
a concentration of 8µg/ml for 3 hours, after which time cultures were prepared as described 
previously for TEM analysis. Nanoparticles were quantified in cell cytosol, vesicles, in nucleus and 
at the basal membrane (“undercell”). Three experiments were performed, each individual 
experiment having three technical repeats. Tukey's multiple comparisons test showed significant 
difference for NP-DNA-40LO cytosol, vesicles and “undercell” compared to NP-Gal (p-value: * 
0.0327, ****<0.0001) and for NP-DNA-40HI vesicles and “undercell” compared to NP-Gal (p-
value: **0.01, ***0.0003). 
 
4.2.4.2  Uptake comparison on 3D co-cultures of the blood-brain 
barrier  
We used co-cultures of endothelial cells grown on astrocytes in a collagen gel as a 3D 
model of the BBB to assess the nanoparticle uptake by counting cells per astrocyte. We 
found higher number of NP-Gal nanoparticles in cytosol of astrocytes as compared to NP-
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DNA-40LO and NP-DNA-40HI (Figure 4.7). Similar numbers of nanoparticles were 
observed in vesicles of astrocytes for all three nanoparticles formulations.  
Next, we calculated the density of nanoparticles in brain endothelial cells, astrocytes and 
collagen from electron micrographs with corresponding dimensions of ultrathin sections. 
Calculating the number of nanoparticles within a known volume provides a true 
representation of how many nanoparticles were transported across the endothelium and 
into the astrocytes and collagen. The results represented in in figure 4.8 shows statistically 
higher numbers of nanoparticles in collagen for NP-DNA-40HI compared to the NP-DNA-
40LO and NP-Gal. Fewer nanoparticles were observed in astrocytes and brain endothelial 


































Figure 4.7 Number of nanoparticles observed in each astrocyte for NP-DNA-40LO and NP-DNA-
40HI compared with NP-Gal. Three experiments were performed, each individual experiment 
having three technical repeats. Tukey's multiple comparisons test showed significant difference for 










Figure 4.8 Uptake efficiency of NP-DNA-40LO and NP-DNA-40HI compared with NP-Gal in the 
brain endothelial cells, astrocytes and in the gel (ECM). Three experiments were performed, each 
individual experiment having three technical repeats. Tukey's multiple comparisons test showed 









Figure 4.9 Uptake assay of NP-DNA-40LO, NP-DNA-40HI and NP-Gal with 3D co-culture model 
of BBB. Brain endothelial cells cultured on top of a collagen hydrogel embedded with astrocytes. 
Silver-enhanced gold nanoparticles (arrows) present in brain endothelial cells hCMEC/D3, 
astrocytes and within a collagen gel (ECM). A representative image from three independent 
experiments is shown, scale bar 2.0 µm.    
85 
 
4.3 Summary and discussion 
In this chapter, we used FPLC as a method to prepare nanoparticle formulations with 
different densities of 40nt dsDNA molecules attached to each nanoparticle: low-density 
nanoparticles (NP-DNA-40LO), and high-density nanoparticles (NP-DNA-40HI). We used 
FPLC because the system is quite advanced with high level of automation which provides 
number of benefits such as; separating different DNA density nanoparticles automatically 
without the need for user intervention during the run. It allows automated collection of 
different DNA density nanoparticles in choice of tubes and in desired volumes while 
providing inline detection that helps in making informed decisions, for example, when the 
column has become equilibrated, when to collect fractions. Other separation method 
available for the fractionating nanoparticles includes electrophoresis (gel or capillary). It 
has the advantage of low consumption of sample and reagents. Nevertheless, nanoparticles 
sample collection by electrophoresis is more challenging (Wei and Lie, 1999).  
The nanoparticle formulations prepared by FPLC were investigated for their uptake 
efficiency compared to control nanoparticles (NP-Gal) into and across brain endothelial 
cells on 2D and 3D models of BBB.  
2D transwell BBB models provides an ease of establishing cultures at low cost making it 
very desirable to be used in various research settings (Cucullo et al. 2008). However, there 
are substantial limitations to the 2D trans-well models that need to be taken into 
consideration. For example, the lack of a three-dimensional structure present in vivo; lack 
of endothelial exposure to physiological shear stress which limits the differentiation of the 
endothelium into a BBB phenotype (Cuculloet al, 2011). Hence, the cells may be presented 
with reduced polarized transport, relative low trans-endothelial electrical resistance 
(TEER) when compared to the BBB in vivo (e.g. isolated brain microcapillaries) and 
corresponding high paracellular permeability to hydrophilic substances (Gastfriend et al, 
2018).  Sreekanthreddy et al, 2012 have shown that the junctional tightness of the 
hCMEC/D3 model may be improved by co-culturing them with astrocytes into a 3D 
model. 
Uptake comparison experiments showed both nanoparticle formulations NP-DNA-40LO 
and NP-DNA-40HI had higher uptake efficiency and appeared more likely at the basal 
membrane of the endothelium compared to uncoated NP-Gal. Theoretically, endocytosis of 
nanoparticles mainly occurs by passive transfer (cytosolic) across the cell membrane into 
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the cytoplasm or by active endocytosis into vesicles (as observed on the electron 
micrographs in chapter 3).  
Our uptake experiments showed that the route of uptake might be affected by the density 
of DNA molecules attached on each nanoparticle.  The subcellular localization indicated 
that NP-DNA-40LO used preferentially cytosolic pathway to enter brain endothelial cell, 
whereas NP-DNA-40HI was entering the cells via vesicular pathways. Both NP-DNA-40LO 
and NP-DNA-40HI were more effective in using vesicular pathway to enter and perhaps 
cross the brain endothelial cells and enter the astrocytes compared to NP- Gal. For future 
studies it would be beneficial to conduct experiments with different time course for the 
uptake experiments in order to find more about the mechanism/route and dynamics of 
different density 40nt DNA-nanoparticles.  
Moreover, investigations of toxicity confirmed no toxicity of up to 3x higher 
concentrations than those used in transport studies, and more than 8x longer nanoparticle 
incubation times. These nanoparticles are safe to use on brain endothelial cells and may be 
safe for other cell types and cell lines due to their low toxicity.   
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5 TISSUE DISTRIBUTION AND INTRACELLULAR LOCALIZATION 
OF NP-DNA-40 IN RATS 
 
Aim:  
The aim of work for this chapter was to assess the tissue distribution and intracellular 
localization of NP-DNA-40 in rats. The objectives were: 
1. To examine the effectiveness of two different nanoparticle administration routes; 
intravenous and intracarotid injections in rats. 
2. To assess uptake of NP-DNA-40LO and NP-DNA-40HI compared to control NP-Gal 
by mass spectroscopy (ICP-MS) to measure gold concentration in the brain, 
cerebellum, liver, spleen, kidney, heart and lungs. 
3. To examine the intracellular localisation of NP-Gal, NP-DNA-40LO and NP-DNA-




The previous chapter examined the uptake of different DNA density nanoparticles (low 
and high) NP-DNA-40 in a 3D co-culture model of the human BBB in vitro. However, the 
situation in vivo may be very different. In this chapter, I explain how route of 
administration as well as size of gold nanoparticles can affect their tissue distribution.  
However, different density NP-DNA-40 have not been administered in rats before and 
assessed for tissue distribution and intracellular localisation by electron microscopy. 
Therefore, we investigated whether these different ratios 40nt DNA-nanoparticles enter the 
brain in vivo and whether we can locate them within the cells of the brain and other organs, 
making a better correlation with the results observed in vitro.  
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5.1.1 Route of administration of gold nanoparticles affects 
tissue distribution 
Route of administration can significantly affect bioavailability of nanoparticles by 
changing the number of biological barriers the nanoparticles face. Currently, there are 
number of administration routes such as Intra-peritoneal injection which directs 
nanoparticles into the blood stream following the infusion at the site of administration 
(Prades et al. 2012; Lasagna-Reeves et al. 2010), orally (Hillyer & Albrecht 2001) as well 
as esophageally (i.e. by gavage) (Schleh et al. 2012), which result in rather low 
bioavailability of drug into the brain. Furthermore, routes of administration can affect the 
tissue distribution profile within an organ. For example, Hirn et al. 2011 demonstrated in 
his research that 18 nm nanoparticles accumulated in the brain after gavage administration 
in large quantities in comparison to other sized nanoparticles (1.4 – 200 nm) but when 
administered via a tail vein injection, these nanoparticles did not show this pattern. 
Therefore, for delivery to the brain, it is important to choose the correct route of 
administration in order to increase the maximum bioavailability of DNA-nanoparticles. 
Previously, gold nanoparticles have been found to enter the brain (Sonavane et al. 2008; 
De Jong et al. 2008; Sousa et al. 2010; Lasagna-Reeves et al. 2010; Hirn et al. 2011) but in 
lower quantities in comparison with other organs. Therefore, in this study, two different 
administration routes were selected to inject nanoparticles to increase the number of 
nanoparticles entering the brain. Intracarotid injection and intravenous injection were 
selected to administer 40nt DNA-nanoparticles in rats for the following reasons; 
 
Previously, gold nanoparticles have been found to enter the brain (Sonavane et al. 2008; 
De Jong et al. 2008; Sousa et al. 2010; Lee et al. 2014; Lasagna-Reeves et al. 2010; Hirn et 
al. 2011). In our study we compared two different administration routes in an attempt to 
optimise the chances of nanoparticles entering the brain. Intracarotid injection and 
intravenous injection were examined for the following reasons; 
 
-       Intracarotid injection (IC) as a route of administration was mainly selected to 
replicate the study of Gromnicova et al. 2014 with the addition of 40nt DNA molecules 
attached to gold nanoparticles. Gromnicova et al. 2014 assessed the uptake of sugar-coated 
gold nanoparticles (similar to NP-Gal) in the brain and overall tissue distribution. Since our 
nanoparticles were very similar, we used the same dose, concentration, time of infusion 
and perfusion/fixation to her methodology.  
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Intracarotid injection is a promising approach to direct the majority of nanoparticles to the 
brain (Walczak et al. 2008). It has been shown to provide a rapid and virtually 
instantaneous high drug concentration in brain vasculature at a fraction of the total 
systemic dose (Joshi et al. 2008). The full dose enters the brain first before being 
distributed throughout the body and diluted in blood. As a result, the IC injection can be 
used as the primary method of drug delivery, increasing the effectiveness of methods for 
brain selective drug delivery (Joshi et al. 2007). Currently, IC-administered drugs are being 
used for the treatment of intractable cerebral vasospasm, intracranial malignancies, and 
ischemic strokes, as well as localizing neurological functions in the brain (Joshi et al. 
2017). The disadvantage of administering nanoparticles through IC injection is that a 
skilled surgical procedure is involved and IC injections may lead to an inconsistent 
distribution of the drug in the brain (Saris et al. 1988). 
 
-       Intravenous injection (IV) is one of the most commonly used administration routes 
for nanoparticle administration directly into the bloodstream (Wiley et al. 2013; Sousa et 
al. 2010). IV injections are minimally invasive, the response is very rapid, with easily 
controlled dosage, and veins are insensitive to irritation by irritant drugs at higher 
concentration. Saxen M, 2016 found that drugs delivered through IV injection circulate 
directly to the brain within 20 to 40 seconds. 
 
 
5.1.2 How gold nanoparticle size and charge affect tissue 
distribution 
Gold nanoparticles with different sizes have been widely assessed for tissue distribution. It 
has been found that small nanoparticles (under 4 nm) are more likely to penetrate cells and 
tissues (Skotland et al. 2010). For example, Hillyer & Albrecht (2001) showed that orally 
fed 4 nm gold nanoparticles accumulated in all organs of mice in high amounts, in contrast 
to 10 nm and 28 nm nanoparticles. Moreover, Schleh et al. (2012) demonstrated that after 
gavage administration, 1.4 nm gold nanoparticles accumulated in all examined organs of 
rats in high amounts in comparison to 2.8 nm, 18 nm or 200 nm nanoparticles. This was 
confirmed by Hirn et al. (2011) who demonstrated correlation of size and retention of gold 
nanoparticles in tissues after IV administration of gold nanoparticles in rats. In their study, 
nanoparticles of 1.4 nm had higher tissue accumulation compared to 5 nm nanoparticles. 
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Therefore, both studies concluded that the smaller the gold nanoparticles, the higher the 
tissue accumulation. 
 
In addition to the size-dependence properties of nanoparticles, the charge has also been 
found to influence tissue accumulation of the nanoparticles. Schleh et al. 2014 found that 
2.8 nm negatively charged nanoparticles accumulated more in organs than positively-
charged ones of the same size. They explained that perhaps negatively charged 
nanoparticles attract and bind onto positively charged proteins found in plasma, making 
them more likely to enter tissues. Moreover, 15 nm nanoparticles (Lee et al. 2014) 
administered intravenously into rats, when charged (carboxyl or amine group giving it a 
negative or positive charge, respectively) penetrated and accumulated in tissues faster than 
neutral PEG-ylated nanoparticles. 
 
 
5.1.3 Function of liver, kidney and spleen  
While the focus of this thesis was mainly assessing the gold nanoparticles localisation in 
brain, it was also important to assess the intracellular localisation of gold nanoparticles in 
liver, spleen and kidney. Liver and kidney plays important role in removing/clearing 
foreign material from body meanwhile phagocytic cells in spleen can initiate immune 
response towards the nanoparticles in order to filter the blood. In order to analyse and 
understand results of these organs, it’s helpful to understand the structure and function of 
each organ. Functions of liver, kidney and spleen are detailed below. 
Liver has many functions in the body, including making proteins, bile production, 
glycogen synthesis, manufacturing triglycerides and cholesterols, blood-clotting factors, 
and far most crucial function breaks down and detoxifies substances in the body. Liver 
helps to break down drugs and medication, including alcohol, and is responsible of 
breaking down hormones and insulin in the body.  
Liver mainly consists of hepatocytes and phagocytic Kupffer cells. Hepatocytes aid the 
detoxification of blood; as the blood passes through the hepatic portal circulation, the 
hepatocytes of the liver remove foreign material and many potentially toxic substances 
from the blood before they can reach the rest of the body. Liver hepatocytes contain 
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enzymes that can metabolize many of these toxins, such as alcohol and drugs, into their 
inactive metabolites. The fixed macrophage Kupffer cells in the liver help to maintain the 
immune system by capturing and digesting bacteria, fungi, parasites, worn-out blood cells, 
and cellular debris. The Kupffer cells can clean a large volume of blood passing through 
the hepatic portal system very quickly.  
The basic function of the spleen is to initiate immune reactions to blood-borne antigens and 
to cleanse the blood of foreign material and old or damaged red blood cells. For this 
purpose, the spleen consists of 2 main compartments, the white and red pulp with an open 
blood circulation system. The white and red pulps are very different in their architecture, 
vascular, cellular composition, and organization (summarised below and illustrated in 
figure 5.1). Also, the spleen is surrounded by a capsule composed of dense irregular 
fibrous tissue, smooth muscle, and elastic fibres. The fibroelastic tissue of the capsule 
contains contractile cells called myofibroblasts. These myofibroblasts cells produce weak 
contractions of the capsule, which helps to discharge the blood stored within the spleen 
into the circulation. Moreover, the capsule allows the spleen to significantly increase in 
size when needed and discharge a large amount of blood into circulation for tissues 
oxygenation (i.e., during physical exercise) (Cesta, M. F, (2006). 
Red Pulp 
- Structure - The red pulp is made up of sinusoids and reticular tissues. The 
sinusoids are leaky with large irregular venous spaces surrounded by thin 
endothelial cells. The endothelial cells have no basal lamina. The direct attachment 
of endothelial cells to the reticular fibers helps to open intercellular gaps making it 
easier for red and white cells to enter and exit. The reticular tissue in the red pulp 
comprises many macrophages, lymphocytes, platelets, and polymorphs.   
- Function - The function of the red pulp (comprising about 80% of splenic tissue) is 
to filter blood and remove foreign material and damaged erythrocytes. Red pulp 
also is a storage site for erythrocytes, iron, and platelets. 
White pulp  
- Structure - White pulp contains lymphoid aggregations, mostly lymphocytes, and 
macrophages which are arranged around the arteries. The lymphocytes are both T 
(mainly T-helper) and B-cells. 
- Function – White pulp comprises about 20% of spleen tissue and plays a role in 




Figure 5.1 Spleen ultrastructure, elucidating red pulp, white pulp and capsule. 
 
The function of the kidney is to filter blood and excrete waste products. Renal corpuscles 
perform the filtration at the end of each kidney nephron; each corpuscle is made up of 
Bowman’s capsule and glomerulus. The glomerulus is surrounded by endothelial cells, 
basal lamina, and an epithelium layer that consists of podocytes with filtration slits 
between them. These filtration slits between podocytes have a thin diaphragm that acts as a 
final filtration barrier before the fluid enters glomerular space (illustrated in figure 5.2). 
Blood that is about to be filtered enters a glomerulus. The large molecules and waste 
products are filtered out of the glomerulus, passing from the Bowman’s capsule through in 
turn, the proximal convoluted tubule, the loop of Henle, the distal convoluted tubule, and a 








Figure 5.2 Renal capsule composed of Bowman’s capsule and glomerulus (top). Bowmans 
capsule (bottom). Image obtained from (Khan academy). 
 
5.2 Results  
Our nanoparticles, despite having the same-size gold core (~2 nm), had a various overall 
size between~2nm to 7.5 nm due to the amount of DNA attached. This might have also 
affected the overall charge – since we would expect that the more DNA attached the more 
negative charge. Hence, our hypothesis was that NP-DNA-40LO and NP-DNA-40HI may 
have different ability to accumulate in different organs, due to the different number of 
DNA molecules attached to nanoparticles and due to the difference in charge (as 
previously shown by Hirn et al. 2011; Schleh et al. 2012; Lee et al. 2014). Furthermore, 
Gromnicova et al, (2014) showed that small gold nanoparticles <5 nm accumulated in 




5.2.1 Intracarotid versus intra-venous administration 
The experiments were performed in collaboration with Koc University (Istanbul) by 
Mehmet Kaya and his colleagues. We used five groups of Wistar Albino male rats, age 
approx. 3 months (weighing 220-340g); three rats per group were injected.  
As it was our first attempt to use intra-venous injection to administer sugar-coated gold 
nanoparticles with DNA attached, we decided to use minimum number of animals for the 
IV injection group to reduce cost and limit numbers of animals. Hence, for this study, we 
decided to not use NP-DNA-40LO for intra-venous injection and compared NP-Gal to NP-
DNA-40HI only (summarised in table 5.1). 
 
Table 5.1 Summary of different groups and number of rats used per group. 
 Intracarotid injection Intravenous injection 
NP-Gal 3 3 
NP-DNA-40LO 3 - 




Figure 5.3 Timeline of the in vivo experiment.   
 
We administered 200µg /per kg rat body weight of NP-Gal, NP-DNA-40LO and NP-DNA-
40HI (gold concentration) over 1 min into the left carotid artery (for IC injection) and the 
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penile vein (for IV injection). The nanoparticles were left to circulate for 10 min in the 
blood (Figure 5.3).  
 
 
5.2.2 The amount of gold in the organs analysed by ICP-MS  
We investigated by ICP-MS the gold concentration in the brain, cerebellum, kidney, liver, 
spleen, heart, lung and blood for animals administered NP-Gal, NP-DNA-40LO and NP-
DNA-40HI 10 min after IC and IV injection.  
The control NP-Gal had accumulated predominantly in kidney within 10 mins of both IC 
and IV injections (figure 5.4 & 5.5), which is consistent with observations for <5 nm-sized 
nanoparticles (Skotland et al. 2010, Hillyer & Albrecht 2001) as they are cleared via this 
organ through the fenestrated endothelium of glomerular capillaries. Compared to kidney 
(4329ng/g), the amount of NP-Gal was much smaller in the brain (91ng/g), liver (50ng/g), 
spleen (132ng/g), and other organs, while some remained in the blood (657ng/g). For both, 
NP-DNA-40LO and NP-DNA-40HI, the nanoparticles accumulated at a high level in the 
liver and spleen for both IC and IV injections (figure 5.4 and 5.5). The quantity of gold 
with DNA observed was much less in kidney (IC-LO:250, HI:112ng/g ) and all other 
organs compared to the liver (IC-LO:1748, HI:1839 ng/g) and spleen (IC-LO:1705, 




Figure 5.4 The amount of gold (per gram of tissue) in different organs determined by ICP-MS 
after 10 mins of nanoparticle infusion in rats with IC injection. The gold concentration in tissue (ng 
Au/ml tissue) was compensated for variations in the dose administered (200µg Au/kg animal). 
Three animals in each group. Dunnett's multiple comparisons test was performed using Graphpad. 
Significant difference was detected between the NP-Gal compared to NP-DNA-40LO and NP-DNA-




Figure 5.5 The amount of gold (per gram of tissue) in different organs after 10 mins of 
nanoparticles infusion with IV- injection analysed by ICP-MS. The gold concentration in tissue (ng 
Au/ml tissue) was compensated for variations in the dose administered (200µg Au/kg animal). 
Three animals in each group. Dunnett's multiple comparisons test was performed using Graphpad. 
Significant difference was detected between the NP-Gal compared to NP-DNA-40LO and NP-DNA-
40HI with for kidney, liver and spleen (****= <0.0001). Data shown as mean ±SEM. 
 
 
5.2.2.1  Gold In brain 
As observed in figure 5.6 and 5.7, the amount of gold accumulated in the brain and 
cerebellum was undetectable. The detection signal of gold by ICP-MS in the brain was 
weak/low in comparison to gold concentration in other organs, and hence negative values 


























































Figure 5.6 The gold content in the brain after 10 mins following IC- injection analysed by ICP-


































Figure 5.7 The gold content in the brain after 10 mins following IV-injection analysed by ICP-




5.2.3 Localisation of nanoparticles in tissues as analysed by 
light microscopy and TEM  
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The main focus of the TEM evaluation was on the brain, kidney, liver, and spleen. Silver 
enhancement staining at light microscopy level indicates overall presence of nanoparticles 
in the tissue samples. Darker staining within the tissue indicates the regions within which 
more nanoparticles were present. All data obtained from light microscopy is non-
quantitative and only gives detail of overall tissue localisation. 
The results from light microscopy and TEM analysis summarised for each organ as follow; 
 
5.2.3.1  Nanoparticles localised in brain 
Light microscopy showed light staining of whole-brain tissue sections, as the sections 
turned slightly brown from unstained white when we incubated the sections with silver 
enhancement (illustrated in figure 5.8 and 5.10). NP-Gal had the most substantial staining 
compared to the NP-DNA-40LO and NP-DNA-40HI. Overall, dark patches of brown 
staining were mostly observed in the region of cortex and median eminence (refer to figure 
5.9) for illustrations of different brain regions) for all three nanoparticles formulations.  
Heavier staining patches were observed on the ipsilateral side (injected side), but light 
staining was also observed on the contralateral side.  
Furthermore, from the results in figure 5.8 we found that within each group (i.e., NP-DNA-
40LO) of treated animals, there were differences in localisation and amount of brown 
staining. For example, with NP-DNA-40LO group, there was one animal with heavier 
brown staining in the cortex, median eminence, choroid plexus, and striatum whereas the 
other two animals showed less or no staining in those regions. Saris et al, 1988 explains a 
possible explanation for variance in staining in the same group, that IC injections can 
provide irregular distribution of administered substance within the brain. There is 
intravascular streaming, which means nanoparticles are based in the part of the brain where 
the stream of blood will flow and hence, carry nanoparticles in that direction. Therefore, 
this can result in a random distribution of the nanoparticles into brain regions, showing a 




Figure 5.8 Brain sections stained with LM silver enhancement to localise gold nanoparticles in 
regions of rat brain of the three intracarotid injected groups;. NP-Gal, NP-DNA-40LO and NP-
DNA-40HI. 3 animals per group were stained. 
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Figure 5.9 Representative regions of the brain as described in this study. Brown/dark staining in 
the section corresponds to the presence of gold nanoparticles. The injected side is noted as 





Figure 5.10 Brain sections stained with silver enhancement to point out regional localisation of 
gold nanoparticles. Brown/dark staining in the sections corresponds to the presence of gold 
nanoparticles (NP-Gal, NP-DNA-40LO and NP-DNA-40HI) in the tissue. The IC injected side is 
noted as ipsilateral, opposite to injected as contralateral side. All images were taken after 2 hours 




When analysed by TEM, NP-Gal, NP-DNA-40LO and NP-DNA-40HI were seen to have 
penetrated the brain endothelium and entered the brain parenchyma (illustrated in figure 
5.11, 5.12 and 5.13). 
    
                         
Figure 5.11 TEM images of brain cortex of IC injected rat with NP-Gal.  Silver-enhanced gold 
nanoparticles found in parenchyma and brain endothelium are identified with black arrows. 
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Figure 5.12 TEM images of brain cortex of IC injected rat with NP-DNA-40LO.  Silver-enhanced 
gold nanoparticles found in parenchyma and brain endothelium are identified with black arrows. 
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Figure 5.13 TEM images of a brain cortex of IC injected rat with NP-DNA-40HI.  Silver-enhanced 
gold nanoparticles found in parenchyma and brain endothelium are identified with black arrows. 





5.2.3.2  Nanoparticles localised in liver  
Results obtained with ICP-MS showed a low amount of gold in the liver of animals treated 
with NP-Gal. On the other hand, high amount of nanoparticles were observed in the liver 
for rats treated with NP-DNA-40LO and NP-DNA-40HI.   
Correspondingly, light microscopy silver enhancement staining showed lighter staining of 
the liver tissue section for the animals treated with NP-Gal. Darker staining indicating 
more nanoparticles was observed for liver tissue sections of animals treated with both NP-
DNA-40LO and NP-DNA-40HI (figure 5.14).  
Next, we looked for localisation of nanoparticles within tissues and cells via TEM. We 
observed few nanoparticles for all three formulations in liver hepatocytes, mostly in their 
cytosol. No nanoparticles were observed in all other liver cells. Liver hepatocytes of 
animals treated with NP-DNA-40LO and NP-DNA-40HI contained more nanoparticles than 
those treated with NP-Gal. Examples of nanoparticles in the liver hepatocytes for animals 
treated with NP-Gal, NP-DNA-40LO and NP-DNA-40HI are presented in Figure 5.15, 5.16 




Figure 5.14 Liver tissue sections stained with LM silver enhancement to point out regions of liver 
where gold nanoparticles were present. Three IC injected treated groups; NP-Gal, NP-DNA-40LO 




                             
 
Figure 5.15 TEM image of a liver tissue section IC injected with NP-Gal. Silver-enhanced gold 
nanoparticles were found in liver hepatocytes but not in Kupffer cells. Nanoparticles are marked 





       
Figure 5.16 TEM images of liver tissue sections IC injected with NP-DNA-40LO.  Silver-enhanced 
gold nanoparticles were found in hepatocytes but not in Kupffer cells. Nanoparticles are marked 




                         
Figure 5.17 TEM images of liver tissue sections IC injected with NP-DNA-40HI. Silver-enhanced 
gold nanoparticles were found in liver hepatocytes but not in Kupffer cells.  Nanoparticles are 
marked with black arrows.  
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5.2.3.3 Nanoparticles localised in spleen  
As previously shown, ICP-MS showed a low level of gold in spleens of animals treated 
with NP-Gal, whereas high amounts were observed in spleens of animals treated with NP-
DNA-40LO and NP-DNA-40HI. However, since spleen tissue sections were darker than all 
other organ sections, it was hard to distinguish any difference when we stained them with 
silver enhancement and observed via light microscopy (figure 5.18).  
Cellular and subcellular localisation via TEM showed very few nanoparticles in red pulp of 
the spleen of animals treated with NP-Gal. Interestingly, no nanoparticles were observed in 
the white pulp and the capsule of the spleen in these animals (figure 5.19).  
Animals treated with NP-DNA-40LO and NP-DNA-40HI had many nanoparticles in 
macrophages of red pulp in the spleen. As with NP-Gal, no nanoparticles were observed in 
the white pulp, but, in contrast to the NP-Gal controls, nanoparticles were observed in the 





Figure 5.18 Spleen tissue sections stained with silver enhancement to point out regions of spleen 
tissue where gold nanoparticles were present. Three IC injected treated groups; NP-Gal, NP-DNA-





Figure 5.19 TEM images of spleen tissue sections IC injected with NP-Gal. Few silver-enhanced 
gold nanoparticles were found in red pulp only but not in white pulp and capsule. Nanoparticles 
marked with arrows. Scale bar = 10 microns. The dashed line in capsule shows separation of 




Figure 5.20 TEM images of spleen tissue sections IC injected with NP-DNA-40LO. Many silver-
enhanced gold nanoparticles were found in red pulp and white pulp but not in the capsule. 
Nanoparticles marked with arrows. Scale bar = 10 microns. The dashed line in capsule shows 




Figure 5.21 TEM images of spleen tissue sections IC injected with NP-DNA-40HI.  Many silver-
enhanced gold nanoparticles were found in red pulp and white pulp but not in the capsule. 
Nanoparticles marked with arrows. Scale bar = 10 microns. The dashed line in capsule shows 
separation of capsule and red pulp.  
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5.2.3.4  Nanoparticles localised in kidney      
ICP-MS showed a relatively high level of gold present in the kidney for animals treated 
with NP-Gal, but low levels in the kidneys of animals treated with NP-DNA-40LO and NP-
DNA-40HI.  
When we performed silver enhancement of kidney sections, we found stained regions all 
over for animals treated with NP-Gal.  In contrast, few stained regions were observed on 
the outer cortex of kidney tissue for an animal treated with NP-DNA-40LO. No staining 
was observed for an animal treated with NP-DNA-40HI (figure 5.22).  
Localization study using TEM showed many NP-Gal nanoparticles in the cytoplasm of the 
proximal tubule epithelium and in the brush borders for kidney tissue (figure 5.23). 
Meanwhile, only a few nanoparticles were observed in the proximal tubule epithelium and 
brush border of animals treated with NP-DNA-40LO and NP-DNA-40HI (figure 5.24 and 
5.25). The distinctive characteristic of the proximal tubule is its luminal brush border, 
which facilitates re-absorption. The re-absorptive function is to remove water and solute 











Figure 5.22 Silver enhanced kidney tissue sections showing regions where NP-Gal, NP-DNA-






Figure 5.23 TEM images of kidney tissue section IC injected with NP-Gal. Silver-enhanced gold 





Figure 5.24 TEM images of kidney tissue section IC injected with NP-DNA-40LO. Silver-enhanced 





Figure 5.25 TEM images of kidney tissue section IC injected with NP-DNA-40HI. Silver-enhanced 




5.3 Discussion and summary 
In this chapter, we investigated the distribution and intracellular localisation of NP-Gal, 
NP-DNA-40LO and NP-DNA-40HI in the organs of rat following administration by two 
different routes; IC injection and IV injection. ICP-MS to quantify gold in tissue samples 
showed that tissue distribution of control nanoparticles NP-Gal was quite different to 
DNA-coated ones of NP-DNA-40LO and NP-DNA-40HI. NP-Gal localised primarily in 
kidney within 10 mins of both IC and IV injections. This is a typical observation for <5 
nm-sized nanoparticles (Skotland et al. 2010, Hillyer & Albrecht 2001) as they are cleared 
through the fenestrated endothelium of glomerular capillaries in kidney. On the other hand, 
both DNA-coated nanoparticles (NP-DNA-40LO and NP-DNA-40HI) primarily 
accumulated in the liver, in particular we found them in cytoplasm of hepatocytes. No 
nanoparticles were observed in all other liver cells. Liver hepatocytes of animals treated 
with NP-DNA-40LO and NP-DNA-40HI contained more nanoparticles than those treated 
with NP-Gal. Moreover, DNA-coated nanoparticles were observed in macrophages of the 
red pulp in the spleen for both IC and IV injections. Our results contrast to those reported 
by Sadauskas, et al, 2007 who found that Kupffer cells/phagocytic cells of liver 
accumulated gold nanoparticles. We did not observe any nanoparticles in Kupffer 
cells/phagocytic cells, maybe because our nanoparticles were much smaller in size 
compared to their 40nm gold nanoparticles. Our nanoparticles were mostly observed in 
hepatocytes which detoxify blood and remove foreign material. Perhaps hepatocytes in 
liver and red pulp cells in spleen were removing NP-DNA-40LO and NP-DNA-40HI from 
the blood. If the distribution of gold nanoparticles is size- or charge-dependent, perhaps the 
negative charge on 40nt DNA-nanoparticles may have attracted (positively charged) 
proteins in the blood, facilitating nanoparticle penetration into liver and spleen. The low 
levels of 40nt DNA-gold nanoparticles observed in kidney may be linked to that the fact 
that NP-DNA-40LO and NP-DNA-40HI are larger - 15 nm than NP-Gal (3.6 nm). Since the 
pores in kidney capillary endothelium are 5.5 nm, nanoparticles smaller than the 5.5 nm 
diameter can enter easily (Joshi et al. 2007).  
In comparison to other organs, the level of gold as detected by ICP-MS was lowest in the 
brain, suggesting that gold nanoparticles cannot cross over the BBB within 10 mins of IC 
and IV injection. This result is quite different from the previous study of Gromnicova et al. 
2016, which claimed that NP-Gal could pass through the BBB and into the brain in vivo. 
Although we observed all three nanoparticle formulations in the brain by TEM localised in 
endothelial and glial cells of the cortex. The difference of our observations in ICP-MS 
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versus TEM might be because we used only anterior half (frozen tissue) for ICP-MS 
analysis, whereas, posterior half was used fixed for TEM analysis. As the nanoparticle 
accumulation can differ depending on the region of the brain (nanoparticles have a 
tendency to accumulate in specific brain regions, where they can access the neural cells, 
including neurons, astrocytes, and microglia) (Caudle, W. M, 2017) and depending on the 
administration route, we may have omitted the gold nanoparticles that were located in the 
posterior half of the brain when doing ICP-MS. Therefore, full brain might need to be 
analysed by ICP-MS.   
There are also several ways to improve BBB targeting drug delivery of gold nanoparticles, 
such as receptor-mediated transcytosis. Receptor-mediated transcytosis may be used to 
facilitate brain targeting drug delivery, by using brain endothelial cells’ receptors, e.g. 
transferrin receptor (Wiley et al. 2013; Prades et al. 2012), or insulin receptor (Shilo et al. 
2014)) to initiate receptor-mediated endocytosis. However, the disadvantage of this 
approach is that targeted receptors (i.e. transferrin receptor or insulin receptor) found on 
brain endothelium for receptor-mediated transcytosis are not only found on the brain 
endothelium but also found on the liver and bone marrow (Simionescu et al. 2002). 
Another way to improve brain selectivity is to use peptides that are not localised in any 
other organs but solely found in the brain. A phage display library has identified peptides 
that are only brain tissue-specific (Pasqualini & Ruoslahti 1996; Rajotte et al. 1998).  It 
would be interesting to bind targeting peptides along with the therapeutic oligonucleotides 
(as there is space for 40 ligand spaces on each nanoparticle) and investigate the targeting 
efficiency of such peptides to increase the uptake of therapeutic nanoparticles in the brain. 
An important limitation of our study was that only 1 time point was selected for analysis – 
10 minutes after the injection. In future studies, long term (with different time points) 
accumulation of nanoparticles in each organ might show fuller picture of how 
nanoparticles are cleared from the body. Additionally, during our in vivo experiments, we 
were encountered with problems in tissue sample delivery from Istanbul, Turkey to UK. 
The fixed (in glutaraldehyde) tissue samples arrived at our lab on dry ice (fully frozen), 
which affected the preservation of the tissue samples and as well as majority of samples 
received were poorly perfused making micro-sectioning of tissue samples incredibly harder 
for electron microscope analysis. Hence, for future studies, it is important to note that 
tissue samples must be perfused well and freezing of fixed samples is avoided.  
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6 ASSESSMENT OF TRANSPORT AND DELIVERY OF DNA VIA 
NP-DNA-40 IN BRAIN ENDOTHELIAL CELLS. 
 
Aim: 
1. To quantify by qPCR how much DNA has been transported across the brain 
endothelial cells. 
2. To determine how the density of DNA on the NPs affects the transport rate of the 
DNA. 
 
Previously, we found that DNA-coated gold nanoparticles entered and possibly crossed 
brain endothelial cells as detected using TEM. However, it is not clear by TEM whether 
DNA from the nanoparticles remained attached and crossed the cells. Since DNA is 
attached covalently to the nanoparticles, it may detach during exposure to reducing 
conditions found in cells. Hence, we decided to assess whether and how much DNA 
attached onto the nanoparticles entered and crossed the endothelial cells. This would help 
us to understand the effectiveness of our gold nanocarriers for transporting 




Quantitative PCR (qPCR) technique is regarded as a standard method currently available 
for DNA quantification. It works in a similar way to a standard PCR but uses real-time 
fluorescence to rapidly measure the quantity of DNA present at each cycle during a PCR. It 
is characterized by high accuracy, time effectiveness, and reproducibility. It is the most 
common molecular technique used for nucleic acid quantification (Huggett and Bustin, 
2011). Therefore, it was chosen to detect the amount of DNA entering and crossing the 





6.2 Results  
The first step in this study was designing primers to detect the 40nt DNA template used to 
attach to gold nanoparticles using these criteria: 
 The primers were complementary to a sequence of nucleotides of the 40nt DNA 
template. While designing the primers, primers matched a sequence within the 
40nt DNA sequence. 
 The primers did not contain complementary regions within themselves, to prevent 
folding over and binding onto themselves to form a hairpin or to prevent forming a 
primer dimer. As the reverse and forward primer sequence was only small between 
20 and 23 nucleotide base pair (bp) in length, the issue of forming hairpin and 
starting off PCR late to miss a portion of DNA sequences was avoided. 
The sequences for primers used; 
 
5’-AATATCGCGGACAGAAGACG-3’           Forward primer for 
40nt 




6.2.1 Testing effectiveness of selected primers by PCR 
A. Test of primers on 40nt DNA without nanoparticles present 
Once the sequence of primers was selected, we examined if these primers work by 
amplifying the 40nt DNA template (without gold nanoparticles at this stage) by PCR 
followed by acrylamide-gel electrophoresis to check amplicon size.  
Figure 6.1 shows a single band at 40bp and light bands of excess primers at the bottom of 
the gel (20 bases) at annealing temperatures of 42 °C and 50 °C. The negative control (MM 






Figure 6.1 6% acrylamide gel showing effective PCR amplification of 40nt DNA template with 
20base reverse and forward primers. The column with MM (Master Mix only- no 40nt DNA 
template) is a negative control. 
 
B. Test of primers on 40nt DNA attached onto nanoparticles 
Next, we tested if the 40nt DNA attached with gold nanoparticles can be detected with the 
primers effectively. A batch of NP-DNA-40 were separated on 5% acrylamide gel, 
transferred onto a nylon membrane and then each band cut into a small strip to place it in 
the PCR reaction for amplification (as illustrated in figure 6.2a). A plain area, where there 
was no band (no NP-DNA-40) was cut as a negative control and 40nt DNA without gold 
nanoparticles was used as the positive control.  
After we amplified NP-DNA-40 bands cut from the nylon membrane by PCR and ran them 
on a gel, we found a successful amplification of NP-DNA-40 by the 20bp reverse and 
forward primers at an annealing temperature of 50 ⁰C (figure 6.2b). Band 1 (NP-DNA-
40HI), which had more 40nt DNA molecules attached to each nanoparticle, showed darker 
band density, confirming that more 40nt DNA molecules were present in band 1 compared 
to band 2. Band 2 (NP-DNA-40LO) showed slightly lighter band density than band 1, 
confirming less 40nt DNA material compared to band 1. The negative control showed no 
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amplification and hence no band, confirming there was no NP-DNA present. Overall, the 




Figure 6.2 a) NP-DNA-40 bands on nylon membrane used to separate distinctive bands from 
excess 40nt DNA. Each band strip was used as a template in PCR at an annealing temperature of 
50 °C with 12, 30 and 35 cycles each. 
 
 
Figure 6.2 b) Effective PCR amplification of separated NP-DNA-40 cut from a nylon membrane, 
as run on a polyacrylamide gel (Figure 6.2a). Band 1 – NP-DNA-40HI, Band 2 – NP-DNA-40LO, 




6.2.1.1 Extension of primers to distinguish an amplified product 
from a primer dimer by-product  
Both reverse and forward 20bp primers were detecting our 40nt DNA template with or 
without gold nanoparticles attached. However, since 20bp primers can form the same 
length (40bp) primer dimer as the amplified 40nt DNA template, it was difficult to 
distinguish between the amplified product and the primer dimer. Therefore, we extended 
the primers sequence by adding a few extra bases to make the final amplified product 
longer. This made the amplified product 48bp long (illustrated in figure 6.3) and easier to 
separate on the gel from the primer dimer by-product.  
 
Extended sequence to make longer amplicons; 
5’CCCGAATATCGCGGACAGAAGACGGAAACCAAGGCAGAGCTTTTGCTC’3 
 
Extended forward primer for 40nt  
5’CCCGAATATCGCGGACAGAAGACG’3  
 
Extended reverse primer for 40nt  




Figure 6.3 An illustration of using 24bp extended primers to amplify 40nt DNA template to create 
a product of 48bp. 
 
We tested the extended primers for their effectiveness in amplification of the target 
sequence (figure 6.4), and observed that it was similar at both annealing temperatures of 46 
°C and 50 °C. The main concern was that a double band was observed when the extended 
reverse and extended forward primers were used to reaction to amplify 40nt DNA. We 
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observed two bands; one at 40bp, and another one at 48/50bp. This may indicate that the 
extended primers were less efficient in the amplification reaction of 40nt DNA, or that one 
of the primers might not have worked properly.   
Therefore, we used the un-extended primers with the extended ones, in the following 
combinations: reverse primer (20bp) with an extended forward primer (24bp), and un-
extended forward primer (20bp) with extended reverse primer (24bp). This created a final 
DNA product of 44bp. Figure 6.5 shows that the combination of un-extended reverse 
primer (20bp) + extended forward one (24bp) had 2 bands. This was similar to what we 
observed with previous combination of both un-extended primers – perhaps the reverse 
primer worked effectively in reaction of amplifying the DNA, but the extended forward 
primer (24bp) did not work as well.  
Finally, the combination of un-extended forward primer (20bp) with extended reverse 
primer (24bp) showed one band, higher than the 40nt marker, indicating that the extended 
forward primer (24bp) amplified the DNA product to the expected length of 44bp. 
. 
 
Figure 6.4 6% acrylamide gel showing amplification by PCR of 40nt DNA by extended primers to 
make a final amplicon of 48bp. Acronyms; MM- master-mix only (without DNA template), non-




Figure 6.5 6% acrylamide gel showing amplification by PCR of 40nt DNA using a reverse primer 
with the extended forward primer and forward primer with extended reverse primer. 20nt, 40nt and 
50bp are the base pairs ladder/marker. Acronyms; R- -Reverse primer (20bp), F- - Forward primer 
(20bp), ER- -Extended reverse primer (24bp), EF—Extended forward primer (24bp). 
 
 
6.2.2 Assessment of DNA from DNA-coated nanoparticles 
crossing the brain endothelial cells. 
Brain endothelial cells (hCMEC/D3) were used for DNA-coated nanoparticle transport 
assay and subsequent DNA quantification by qPCR. The uptake and crossing of cells with 
NP-DNA-40LO and DNA-40HI (refer to chapter 2.2.1 for 2D assay and 2.2.2 for 3D assay) 
was assessed. For qPCR analysis, the cells were rapidly frozen. 
Our initial plan was to use co-cultures of brain endothelial cells and astrocytes in 3D 
collagen gel to assess the localization of DNA cargo from NP-DNA-40LO and NP-DNA-
40HI. However, the astrocyte co-cultured gel contracted during several attempts (see 
example in Figure 6.6). The contracted co-cultures made it unusable for transfer studies 
since nanoparticles could pass around the monolayer of brain endothelial cells and enter 
the gel without crossing the endothelium first. Therefore, we had to use monolayers of 





Figure 6.6 Collagen gels embedded with astrocytes showing contraction (gels pulled away from 
the edge of wells-arrows). Due to this monolayer of D3 cells could not form and the 3D co-cultures 
could not be established. 
 
 
6.2.2.1 qPCR preparation and standard curve to determine DNA 
levels in different compartments 
For qPCR quantification purposes, 4 treatment groups were selected; 40nt dsDNA alone, 
NP-Gal, NP-DNA-40LO, NP-DNA-40HI. 8µg/mL of nanoparticles for each group were 
applied to brain endothelial cells grown on trans-well inserts and incubated for 3 hours. 
Then, medium was collected from the top (apical side) and bottom (basal side) of the 
transwell. The hCMEC/D3 cells were lysed with 1% triton and frozen immediately at -20 










Free 40nt dsDNA 
Figure 6.7 2D transfer assay performed with four different groups to collect samples for qPCR 
quantification of 40nt DNA. 
 
The lysed cells, top and base media samples were used for DNA quantification. qPCR 
using SYBR Green (x2) Master Mix was performed to quantitate the 40nt DNA in this 
study. For all qPCR reactions, 20bp forward primers with 24bp (extended) reverse primer 
were used to amplify the final DNA product to 44bp. We tested a number of different 
primer concentrations ranging between 0.25 µM to 1 µM; all worked well, but 0.5 µM was 
selected as recommended by the manufacturer.   
After the amplification, the qPCR readout of DNA measurement is given out in Cycles to 
Threshold (Ct) of PCR, a relative value that represents the cycle number at which the 
amount of amplified DNA reaches the threshold level. A high Ct value represents a low 
level of DNA, while higher expression of DNA in the sample will have low Ct value.  In 
order to normalise Ct value in the quantitative measure (µg/mL), a standard curve was 
used. 
To prepare a qPCR standard curve, qPCR reactions were set up to amplify different 





For this study, 3 different 40nt DNA sample standard curves were prepared;  
- Free 40nt DNA  
- NP-DNA-40LO 
- NP-DNA-40HI 
Each of the three above DNA sample standard curve was prepared using 13 serial dilutions 
of DNA with a dilution factor of 1:10 in water. The diluted amounts were;  
-       1 x10-3µg, 1 x10-4µg, 1 x 10-5µg, 1x 10-6µg, 1x 10-7µg, 1x 10-8µg, 1x 10-9µg, 1x 10-
10µg, 1x 10-11µg, 1x 10-12µg and 1x 10-13µg. 
The reaction with no DNA template-negative control (SYBR green Master Mix and 
primers only) gave Ct value of 22.3. Hence, the DNA template was diluted to a 
concentration which will give Ct value similar to 22 cycles. The Ct values (x-axis) of 
qPCR from all known serial dilutions (y-axis) were used to make a linear regression curve 
slope and used to calculate the amplification efficiency for the transfer assay experiment. 
Figure 6.8 illustrates an example of a qPCR standard curve.   
Example of how the Ct value was converted to the absolute value of DNA: 
The standard curve gave us straight line equation y= -14347x + 15.931 
The y is known Ct value given by the qPCR and we work out unknown, x, which will be 
the amount of DNA. For example; 
The negative control had Ct cycle of 22.3; 
                       x =  (22.3 -15.931)/-14347 
                       x =  - 4 x10-4µg= (negative value means there is no DNA) 
 
The positive control (free 40nt dsDNA) gave a Ct value of 14.3; 
                       x = (14.8 – 15.931)/-14347 
                       x = 7.8 x10-5 µg (the sample was diluted 1µl in 10,000)   
                Hence,   x = 0.78 µg 




Figure 6.8 A representative qPCR standard curve for 40nt DNA attached onto nanoparticles (NP-
DNA-40). The dotted line is the straight line. 
 
The results from the quantification of DNA in the 2D BBB transfer assay is summarised in 
figure 6.9. A comparison was performed for 4 treated groups: NP- Gal (negative control), 
DNA without nanoparticles, NP-DNA-40LO AND NP-DNA-40HI. The Ct values 
determined by qPCR for each sample were normalised using a standard curve. The 
negative control with primers and SYBR Green Master mix (no DNA template) had Ct 
value of 23; therefore, all values over 23 cycles were negative and considered zero. The 
qPCR results showed higher than 23 Ct cycles for the top media, in cells and in the base 
media for the cellular trans-wells treated with NP-Gal, which we expected from the NP-
Gal as this was our negative control.  Endothelial cells treated with NP-DNA-40LO showed 
the highest transfer of DNA across the cells and into the base media compared with NP-
DNA-40HI and DNA alone. The cells treated with NP-DNA-40HI had higher transfer of 
DNA across and into the basal chamber of the trans-well than those treated with DNA 
alone. About half of the DNA found in top media (~0.9µg) for NP-DNA-40LO was found 
in the base media (0.4 µg) which shows that NP-DNA-40LO were enhancing the uptake of 
DNA across the brain endothelium compared to the NP-DNA-40HI and DNA alone. Lastly, 




























































Figure 6.9 qPCR quantification of 40nt DNA measured in each sample of NP-Gal, free 40nt 
dsDNA, NP-DNA-40LO and NP-DNA-40HI collected from 2D transfer assay (values normalised 
using relative standard curve), n=3. Tukey's multiple comparisons test was performed using 
GraphPad. There is a significant difference for NP-DNA-40LO and NP-DNA-40HI bottom chamber 
compared to NP-Gal (p-value: ****<0.0001). 
 
6.3 Summary and discussion 
In this chapter, we tested the transport efficiency of 40nt DNA cargo using 
glyconanoparticles coated with DNA across the brain endothelial cells. There are three 
most common methods for DNA or RNA quantitation: spectrophotometry, fluorescence 
and real-time PCR. Real-time PCR as method of DNA quantification was selected in our 
study because it offers the most sensitive detection, as low as picogram quantities of 
nucleic acid (since we were working with small amount of DNA in the trans-well 
experiments, it was rational to use such sensitive technique). Additionally, real-time PCR 
also proved accurate quantification of nucleic acids of interest, even in the presence of 
common contaminants, other nucleic acids, primers and free nucleotides (because of the 
sequence-specific target PCR primers). Although, reagents used for real-time PCR are 
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costly and require advanced instrumentation. UV Spectrophotometry provides quick and 
simple alternative to real-time PCR as it does not require any reagents, however the 
technique would be unfeasible for our experiment as it would not identify our specific 
DNA sequence (as opposed to all the DNA in the cells) and also has limited low-end 
sensitivity. Lastly, DNA quantification by fluorescence technique also could not be used 
for our study. This is because gold nanoparticles are able to quench fluorescence, 
especially if they are less than 40 nm in diameter (Swierczewska et al. 2011). Quenching 
happens when a gold nanoparticle is at a certain distance from a fluorophore (Dulkeith et 
al. 2005); the nanoparticle’s surface plasmon resonance may change the 
excitation/emission property of the fluorophore, preventing it from emitting light (Kang et 
al. 2011). 
We measured the amount of DNA transported across via the following nanoparticle 
formulations: NP- Gal (negative control), free 40nt dsDNA, NP-DNA-40LO and NP-DNA-
40HI. The primers were tested for the 40nt DNA with nanoparticles using standard semi-
quantitative PCR followed by polyacrylamide gel.  We amplified the 40nt DNA-gold 
nanoparticles into a 44bp long DNA using reverse and forward primers, so that the 
amplified product could be distinguished from the 40nt DNA template and from 
concatenated primer-dimers. We found that NP-DNA-40LO and NP-DNA-40HI were able to 
transport 40nt DNA cargo across the brain endothelium. NP-DNA-40LO appeared to be 
most efficient in transporting DNA across brain endothelium. The material applied (top 
chamber) was roughly between 0.8-0.9 µg and about 0.3 -0.4 µg was transported across 
with the NP-DNA-40LO. These findings also are consistent with our earlier studies using 
TEM where we observed higher uptake of NP-DNA-40LO nanoparticles across brain 
endothelium than NP-DNA-40HI.  
Since brain endothelial cells hCMEC/D3 are a cell line and therefore might not form tight 
junctions as primary cells or in vivo, we tested movement of free 40nt dsDNA across the 
trans-well system with monolayer of brain endothelium. We found no free 40nt dsDNA at 
the basal chamber of the insert therefore, we were confident in the result since we did not 
observe unspecific penetration of our trans-well system (with cell monolayer) by free 40nt 
dsDNA. Furthermore, DNA was also found in cells in a small amount for NP-DNA-40LO 
and NP-DNA-40HI, and hence future studies could be performed with longer incubation 
times (longer than 3 hours) to test if more NP-DNA-40 may be transported across.  
Correspondingly, for future studies it will be beneficial to analyse gold content (applied in 
the top chamber) along with the DNA content by the qPCR versus the bottom chamber to 
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see what percentage of gold nanoparticles are still holding onto the DNA or whether some 
have already lost the DNA in cells. As from the qPCR DNA quantification alone we 
cannot tell whether the DNA in the bottom chamber is attached to the gold nanoparticles or 
is freely floating there without nanoparticles. Gold concentration can be measured by 




Oligonucleotide-based therapeutics are becoming the third major drug development 
platform. They are mainly focused on CRISPR (Gene editing), RNA interference (RNAi, 
to reduce gene expression) as well as using antisense oligonucleotides (to silence a gene). 
The development relies on the fact that oligonucleotides based therapeutics can delay the 
disease onset or halt the disease progression through target gene knockdown, knockout or 
splicing modulation (Evers et al, 2015). In 2018, Spinraza®, an antisense oligonucleotide 
drug was approved as a splicing modulator for the survival of motor neuron gene for the 
treatment of spinal muscular atrophy by the US Food and Drug Administration (Stein et al. 
2017). However, such antisense oligonucleotide drugs require administration via highly 
invasive routes, e.g., intrathecal administration, because the accessibility of the antisense 
oligonucleotide drugs to the CNS through the bloodstream is very low as the BBB 
effectively prevents their entry into the brain.  The BBB prevents free permeation of 
molecules larger than 400 Da, including oligonucleotide therapeutics (~6,600 Da or 
larger), between the bloodstream and the brain parenchyma (Crawford et al, 2016). 
Therefore, systemic oligonucleotides based therapeutics delivery to the brain remains 
challenging. Here, with the aim of tackling this issue, we developed small gold 
glyconanoparticles covalently attached with DNA capable of crossing the BBB. Gold 
glyconanoparticles were coated using place-exchange reaction with different length and 
density of oligonucleotides and assessed for their efficiency in crossing the BBB in vitro 
and in vivo. 
 
In chapter 3, we showed how these nanocarrier formulations were prepared and 
characterised. The experimental approach used a thiol-attached DNA oligonucleotide 
covalently attached onto galactose-coated gold nanoparticles. EMSA was used to separate 
nanoparticles with different numbers of DNA molecules attached. Six different bands were 
observed on EMSA, perhaps demonstrating that up to 6 DNA can bind onto a single 
nanoparticle. Next, formulations of NP-DNA-20ss, NP-DNA-20ds and NP-DNA-40ds were 
prepared and assessed for their transport rate across the brain endothelial cell line 
hCMEC/D3. We found that despite their net negative charge, DNA coated nanoparticles 
had higher cellular uptake than their uncoated equivalent, galactose-coated gold 
nanoparticles (NP-Gal). This investigation highlighted the possibility that attaching more 
DNA onto each nanoparticle may increase their uptake efficiency. However, the 
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nanoparticle formulations contained a mixture of free DNA and unreacted NP-Gal, so it 
was not possible to determine whether the detected nanoparticles entering the cells were 
unreacted NP-Gal or indeed NP-DNA. Since the nanoparticle mixture also contained free 
excess unreacted DNA, this might have affected cell membrane permeability. Therefore, 
we needed to remove the unreacted material from the nanoparticle mixture. 
In chapter 4, we used FPLC to remove unreacted material and isolate only NP-DNA-40ds. 
We were able to isolate different density of 40nt DNA-coated nanoparticles also 
using FPLC. Two fractionated formulations (NP-DNA-40LO and NP-DNA-40HI) were 
then investigated for their uptake efficiency into and across brain endothelial cells and 
astrocytes using an in vitro 3D co-culture model of the BBB. Both NP-DNA-40LO and NP-
DNA-40HI were more effective in crossing the brain endothelial cells and entering 
astrocytes compared to control uncoated NP-Gal. Therefore, attaching 40nt long DNA 
molecule did not hinder the transport of the nanoparticles across brain endothelial cells. 
We also assessed cytotoxicity of DNA-coated nanoparticles on human brain endothelium 
(hCMEC/D3) and found none of the formulations to be cytotoxic up to 3x higher 
nanoparticles concentrations than those used in transport studies, and more than 8x longer 
nanoparticle incubation times. Hence, nanoparticles are safe to use on brain endothelial 
cells and may be safe for other cell types and cell lines due to their low toxicity. 
In chapter 5, we investigated tissue distribution of DNA-coated nanoparticles in 
vivo. Rats were dosed with the nanoparticles via two different administration routes: 
intracarotid injection (an approach that has never been used in the application of DNA-
gold nanoparticles before) and intravenous injection (a more accessible route). The 
nanoparticles circulated in the body for 10 minutes to capture the first encounter of gold 
nanoparticles in the brain. We found nanoparticles of all three formulations (NP-Gal, NP-
DNA-40LO and NP-DNA-40HI) in the brain endothelial cell and glial cells of the rat cortex 
using TEM. We observed typical clearance of NP-Gal via the kidney.  The more negatively 
charged nanoparticles coated with DNA were localised in liver and were observed in the 
cytoplasm of hepatocytes in the liver, and macrophages of the red pulp in the spleen. 
In Chapter 6, we quantified whether and how much DNA cargo is transported via DNA-
coated nanoparticles across brain endothelial cells. qPCR results demonstrated that NP-
DNA-40LO and NP-DNA-40HI successfully transported 40nt DNA cargo across the brain 
endothelium. Out of the two nanoparticle-DNA formulations, there was higher transport of 
DNA across brain endothelium using NP-DNA-40LO than NP-DNA-40HI (~0.9µg of the 
nanoparticles found on the apical side (top cell culture media) and ~0. 4µg of DNA was 
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found on the basal side media).  We were confident in this result since we did not observe 
unspecific penetration of our trans-well system (with cell monolayer) by free DNA. 
Overall, from the amount of DNA observed crossing the endothelial cells in our studies, it 
suggests that we may be able to treat disorders that require single gene editing or where 
one time immediate treatment is required (in cases of acute brain disorder), whereas 
delivery of therapeutic DNAs for disorders that require continuous treatment needs further 
investigation (discussed in detail later on in this chapter). 
In conclusion, the results in our project demonstrated the possibility to deliver 40nt DNA 
oligonucleotide across the BBB on ~ 2nm gold glyconanoparticles. Therefore, this system 
may be useful to deliver DNA oligonucleotides into the brain. The NP-Gal covalently-
attached with 40nt thiol DNA have not been prepared before and /or tested for their uptake 
efficiency on in vitro and in vivo models.  
 
Uptake and transport of nanoparticles by endothelial cells in vitro 
In 2D cell uptake assays, the nanoparticles with more DNA attached were more effective 
in crossing the brain endothelial cells using the vesicular pathway. NP-DNA-40ds had 
significantly higher uptake efficiency in both cytosolic and vesicular transport across brain 
endothelial cells and showed a significantly higher number of nanoparticles crossing the 
cell from the apical side (blood) and onto the basal (brain side) compared with NP-DNA-
20ds and NP-Gal.  
When we co-cultured our brain endothelial cells with astrocytes embedded in 3D collagen 
gel, NP-DNA-40HI had higher transport of nanoparticles across the brain endothelial cells 
and into the astrocytes than did NP-DNA-40LO and NP-Gal. Additionally, it was observed 
that the possibly larger nanoparticles (with more DNA molecules) had a tendency to use 
the active vesicular pathway rather than the passive cytosolic pathway to enter cells. 
Perhaps size may be a key to determine the uptake pathway of the nanoparticles. The 
phenomenon of nanoparticle size and its effect on the trans-cellular pathway has been 
extensively investigated on many different cell lines by Chithrani et al, 2006. They found 
that 40nm gold nanoparticles were taken up preferentially via active vesicular pathway 
whereas 2nm nanoparticles were taken up via passive cytosolic pathway.  
Lastly, the DNA quantification by qPCR showed DNA material crossing to the basal side 
(brain side) for NP-DNA-40LO and NP-DNA-40HI within 3 hours. NP-DNA-40LO appeared 
to be most efficient in transporting DNA across brain endothelium. The material applied 
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(top chamber) was roughly between 0.8-0.9 µg and about 0.3 -0.4 µg was transported 
across with the NP-DNA-40LO. This shows effective DNA delivery across the brain 
endothelial cells using gold nanoparticles. Hence, attaching longer and more DNA 
molecules on NP-Gal did not hinder the transport of the nanoparticles across the brain 
endothelial cells. In fact, the opposite was observed as the transport across brain 
endothelium was enhanced with the DNA bound nanoparticles compared to NP-Gal. 
 
Distribution of nanoparticles in vivo 
Different density 40nt DNA attached gold nanoparticles have not been administered into 
rats before and assessed for bodily distribution and intracellular localisation by electron 
microscopy. Markedly different tissue distributions were observed for NP-Gal compared to 
NP-DNA-40LO and NP-DNA-40HI. The smaller NP-Gal had moved to the kidney within 10 
mins of both intravenous and intracarotid injections which is consistent with reports of <5 
nm-sized nanoparticles  being released into the urine as a result of simple filtration through 
the renal glomeruli (Skotland et al. 2010, Hillyer & Albrecht 2001). In contrast, both the 
NP-DNA-40LO and NP-DNA-40HI accumulated preferentially in the liver and spleen 
following both intravenous and intracarotid injections.  
In our in vivo study, the results differed from previous studies in terms of which cells the 
nanoparticles were taken up by/localised in the liver. Sadauskas et al. (2007) explained that 
the bigger size (size-dependent) nanoparticles are most likely to be taken up by the 
phagocytic cells in liver, whereas results in our study demonstrated that nanoparticles were 
mostly observed in cytoplasm of hepatocytes rather than the Kupffer cells/phagocytic cells 
of liver, although, the nanoparticles used in the Sadauskas study (2007) were 40nm (much 
larger than our nanoparticles). 
With regard to the to the brain, our studies found very low levels of gold concentration 
detected by ICP/MS in the brain for all three nanoparticle formulations (in vivo), 
suggesting that gold nanoparticles cannot cross over the BBB at 10 mins after intracarotid 
and intravenous injection. Nonetheless, gold nanoparticles were observed in the brain 
endothelial cells and glial cells of the cortex of the brain in the same study for all three 
nanoparticle formulations when analysed by TEM. Perhaps, low gold concentration 
detected by ICP-MS may be due to the fact that only the anterior half sample was used for 
gold quantification rather than the whole brain.  Previously, Gromnicova et al, 2016, 
demonstrated the same formulation of NP-Gal (used in this project) crossed through the 
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BBB and accumulated in the brain in vivo. Hence, this strongly needs to be repeated and a 
whole brain should be used when measuring the gold concentration by ICP-MS. 
 
7.1 Consequences of therapy using gold nanoparticles  
When considering drug delivery of nucleic acids using gold nanoparticles, three aspects 
need to be considered:  
a) Acute conditions, immediate and fast treatment are needed;  
b) Chronic conditions, treatment needs to be given over a long period.  
c) Correction of genetic disorders, single dose that permanently corrects the defective gene  
 
In an acute condition such as traumatic brain injury, the action of nanoparticle drug therapy 
needs to be immediate (rapid penetration of nanoparticles in the brain and release of 
therapeutic agent), to facilitate neuronal self-repair or control the expression of a gene that 
leads to neuronal cell death. For this treatment, the speed of complete clearance of gold 
nanoparticle carrier from the body may not be relevant.  Our study showed (in chapter 5) 
electron microscope images of the brain tissue, where, within a small amount of time (10 
mins) the NP-DNA-40 has already accessed the brain parenchyma. Hence, NP-DNA-40LO 
may be useful in treatment of brain disorders that require single immediate therapy  
Meanwhile, for chronic brain conditions such as Alzheimer’s disease, Parkinson’s disease 
or amyotrophic lateral sclerosis (ALS), the application of a treatment needs to be long-term 
(i.e., siRNA or antisense oligonucleotide therapy requires repeated administration for long-
term down-regulation of an abnormal gene expression to control the disease growth. For 
such treatments, it is necessary to know the time of complete bodily clearance of 
therapeutic gold nanoparticles. In chapter 5, we showed that NP-DNA-40 accumulate in 
liver and spleen mostly, however, the long term accumulation of NP-DNA-40 within each 
organ and body clearance has not been studied yet. Therefore, the cumulative effect of 
long-term administration of NP-DNA-40LO and NP-DNA-40HI in organs over a long period 
of time would need to be investigated in animal studies before considering the current 
nanoparticle therapy for chronic brain diseases. 
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As for single gene defect disorders like Huntington’s disease, using CRISPR/Cas9 gene 
therapy could achieve the benefits through a single dose that permanently inactivates the 
defective gene. Whereas, if it involves antisense oligonucleotides then it may require long-
term, repeated administration to provide sustained benefits, which as mentioned earlier 
requires more investigation of long term clearance from the body. 
 
7.2 Clinical use  
Gold glyconanoparticles have a potential to be used in the clinic, since they have already 
been approved for use in clinical trials for treating prostate cancer (Libutti et al. 2010) and 
clinical drugs have been attached to nanoparticles for treatment of heart diseases (Zhang et 
al, 2018). Our industrial partner Midatech has already had one of their formulations of gold 
nanoparticles coated with PEG-amine/galactose/insulin in a clinical trial. These 
formulations of nanoparticles are deemed safe by the FDA (Midatech Pharma, personal 
communication).  
In terms of what happens to nanoparticles when they enter the brain, it has been 
demonstrated by Midatech that small 2nm nanoparticles are substantially removed from 
the brain and other organs after 24 hours (Midatech Pharma, personal communication). A 
study by Sela et al. (2015) also showed rapid initial accumulation in the brain of 1.3 +/-
0.3nm size gold nanoparticles, reaching a maximum level in brain after 6–16 h, followed 
by a fast decline until it levels out after about 24hr and then slowly decreases to a 
negligible level.  
Our NP-Gal might start to clear out from the body after 24hrs. As for NP-DNA-40, they 
are not excessively larger in size (~8nm) compared to NP-Gal but do have a high negative 
charge which might cause opsonisation and may cause the NP-DNA-40 to clear out from 
body earlier than NP-Gal or via a different route. Once nanoparticles enter the body, 
opsonin proteins might attach to aid their clearance via the mononuclear phagocytic system 
(MPS) (Owens et al, 2006).  
 
7.3 Concluding remarks 
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Overall, despite the early stages in the development, our studies have shown improvement 
in the bioavailability of oligonucleotides in the brain carried by nanoparticles, due to the 
rapid penetration in a short time. Hence, it may be a useful agent to treat acute brain 
disorders or disorders that require editing of single gene using CRISPR/Cas9 by 
administration of intracarotid or intravenous injection. The chronic brain conditions need 
further investigation into the long term (with different time points) accumulation of 
nanoparticles in each organ and clearance from the body. While gene delivery represents 
an important aspect of gold nanoparticles, diagnostics, as well as imaging techniques can 
also benefit enormously (most notably bioimaging) as gold nanoparticles can be visualised 
by MRI , making them potentially an important tool in the diagnosis of brain disorders. 
Although this is a broad area of research it has enormous potential.  
 
7.4 Future studies 
For future in vitro studies; the detailed BBB-crossing mechanism of negatively charged-
DNA coated nanoparticles, along with interaction mechanism of negative charge with 
endothelial surface protein needs further investigation. Also, for future studies it will be 
beneficial to analyse gold content (applied in the top chamber) along with the DNA content 
by the qPCR versus the bottom chamber  to see what percentage of gold nanoparticles are 
still holding onto the DNA or whether some have already lost the DNA in cells. From the 
qPCR DNA quantification alone we cannot tell whether the DNA in the bottom chamber is 
attached to the gold nanoparticles or is freely floating there without nanoparticles. Gold 
concentration and characterisation can be measured by spectrophotometric gold assay 
using the gold standard (AAS 1000 mg/ml, Sigma) or by mass spectrometry. 
There is also a strong need to repeat the in vivo study with administration of 40nt DNA-
nanoparticles using a whole brain when measuring the gold concentration by ICP-MS and 
having different time measures to assess the long term accumulation of 40nt DNA-
nanoparticles within each organ and the cumulative effect of long-term administration of 
NP-DNA-40LO and NP-DNA-40HI in organs before considering nanoparticle therapy for 
chronic brain diseases. Moreover, we still have to explore attachment of Cas9 protein with 
our 40nt DNA-nanoparticles and assess the transport of 40nt DNA-nanoparticles with Cas9 
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